# EDGAR Filing Document

**Accession Number:** 0001839285
**File Stem:** 0001213900-26-056096
**Filing Date:** 2026-5
**Character Count:** 165231
**Document Hash:** 3d9257b323dd69a6300d3ee6eadad87a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-056096.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001213900-26-056096

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 92

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Healthcare Triangle, Inc.
- **CENTRAL INDEX KEY:** 0001839285
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 843559776
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40903
- **FILM NUMBER:** 26975325

**BUSINESS ADDRESS:**
- **STREET 1:** 4309 HACIENDA DR.
- **STREET 2:** SUITE 150
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 945888
- **BUSINESS PHONE:** 925-270-4812

**MAIL ADDRESS:**
- **STREET 1:** 4309 HACIENDA DR.
- **STREET 2:** SUITE 150
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 945888

?xml version='1.0' encoding='ASCII'?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number 001-40903

**HEALTHCARE TRIANGLE, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-3559776** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |
| **7901 Stoneridge Drive, Suite 210 Pleasanton, CA** | **94588** |
| (Address of principal executive officer) | (Zip Code) |
| **(925) 270-4812** | **(925) 270-4812** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker Symbol(s) | Name of each exchange on which registered |
| **Common Stock, $0.00001 par value** | **HCTI** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

As of May 13, 2026, 2,027,783 shares of the registrant's common stock, $0.00001 par value per share, were issued and outstanding.

**Table of Contents**

---

| | |
|:---|:---|
| [Note About Forward-Looking Statements](#a_001) | ii |
| **[PART I – FINANCIAL INFORMATION](#a_002)** | 1 |
| [Item 1. Financial statements](#a_003) | 1 |
| [Unaudited Condensed Consolidated Balance sheets](#a_004) | 1 |
| [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](#a_005) | 2 |
| [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)](#a_006) | 3 |
| [Unaudited Condensed Consolidated Statements of Cash Flows](#a_007) | 4 |
| [Notes to Unaudited Condensed Consolidated Financial Statements](#a_008) | 5 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_009) | 28 |
| [Item 3. Quantitative and Qualitative Disclosures About Market Risk](#a_010) | 39 |
| [Item 4. Controls and Procedures](#a_011) | 39 |
| **[PART II - OTHER INFORMATION](#a_012)** | 40 |
| [Item 1. Legal Proceedings](#a_013) | 40 |
| [Item 1A. Risk Factors](#a_014) | 40 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#a_015) | 40 |
| [Item 3. Defaults Upon Senior Securities](#a_016) | 40 |
| [Item 4. Mine Safety Disclosures](#a_017) | 40 |
| [Item 5. Other Information](#a_018) | 40 |
| [Item 6. Exhibits](#a_019) | 41 |
| [Signatures](#a_020) | 43 |

---

i

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including the sections titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors," contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, involving substantial risks and uncertainties. The words "believe," "may," "will," "potentially," "plan," "could," "should," "predict," "ongoing," "estimate," "continue," "anticipate," "intend," "project," "expect," "seek," or the negative of these words, or terms or similar expressions conveying uncertainty of future events or outcomes, or that concern our expectations, strategy, plans or intentions, are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or expected. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements discussed under the heading "Risk Factors" and in our publicly available filings and press releases. These statements include, among other things, those regarding:

● our ability to continue to add new customers and increase sales to our existing customers;

● our ability to develop new solutions and bring them to market in a timely manner;

● our ability to timely and effectively scale and adapt our existing solutions;

● our dependence on establishing and maintaining a strong brand;

● the occurrence of service interruptions and security or privacy breaches and related remediation efforts and fines;

● system failures or capacity constraints

● the rate of growth of, and anticipated trends and challenges in, our business and in the market for our products;

● our future financial performance, including our expectations regarding our revenue, cost of revenue, operating expenses, including changes in technology and development, marketing and advertising, general and administrative and customer care expenses, and our ability to achieve and maintain future profitability;

● our ability to continue to efficiently acquire customers, maintain our high customer retention rates and maintain the level of our customers' lifetime spend;

● our ability to provide high quality customer care;

● the effects of increased competition in our markets and our ability to compete effectively;

● our ability to grow internationally;

● the impact of fluctuations in foreign currency exchange rates on our business and our ability to effectively manage the exposure to such fluctuations;

● our ability to effectively manage our growth and associated investments, including our migration of the vast majority of our infrastructure to the public cloud;

● our ability to maintain our relationships with our partners;

● adverse consequences of our substantial level of indebtedness and our ability to repay our debt;

● our ability to maintain, protect and enhance our intellectual property;

ii

● our ability to maintain or improve our market share;

● our ability to continue generating cashflows and to maintain sufficiency of cash and cash equivalents to meet our needs for at least the next 12 months;

● beliefs and objectives for future operations;

● our ability to stay in compliance with laws and regulations currently applicable to, or which may become applicable to, our business both in the United States (U.S.) and internationally;

● economic and industry trends or trend analysis;

● our ability to attract and retain qualified employees and key personnel;

● anticipated income tax rates, tax estimates and tax standards;

● interest and other embedded rate changes;

● the future trading prices of our common stock;

● our expectations regarding the outcome of any regulatory investigation or litigation;

● the amount and timing of future repurchases of our common stock under any share repurchase program;

● the potential impact of shareholder activism on our business and operations; and

● the length and severity of pandemics and their impact on our business, customers and employees; as well as other statements regarding our future operations, financial condition, growth prospects and business strategies.

We operate in very competitive and rapidly changing environments, and new risks emerge from time-to-time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report may not occur, and actual results could differ materially and adversely from those implied in our forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this report to confirm such statements to actual results or to changes in our expectations, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless expressly indicated or the context suggests otherwise, references to "Healthcare Triangle," "company," "we," "us" and "our" refer to Healthcare Triangle Inc. and its consolidated subsidiaries.

iii

**PART I**

**FINANCIAL INFORMATION**

**Item 1. Financial statements (In thousands of US $, unless otherwise noted)**

**HEALTHCARE TRIANGLE, INC.**

**Condensed Consolidated Balance Sheets**

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**Note** | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
|  |  | **(Unaudited)** | **(Audited)** |
| **Assets** |  |  |  |
| **Current assets** |  |  |  |
| Cash and cash equivalents |  | $4315 | $7625 |
| Accounts receivable, net | 3 | 8367 | 2070 |
| Advances | 8 | 3826 | 3826 |
| Other current assets | 4 | 2387 | 3456 |
| Total current assets |  | 18895 | 16977 |
| Furniture and equipment, net | 6 | 1330 | 5 |
| Other intangible assets, net | 5 | 55219 | 2808 |
| Goodwill | 5 | 2946 | 2946 |
| Operating lease right-of-use assets | 7 | 1166 | - |
| Other non-current assets |  | 204 | - |
| Deferred tax asset |  | 402 | - |
| **Total assets** |  | $**80162** | $**22736** |
| **Liabilities and stockholders' equity** |  |  |  |
| **Current liabilities** |  |  |  |
| Accounts payable |  | $3288 | $744 |
| Short-term borrowing | 9 | 9088 | 10737 |
| Operating lease liabilities | 7 | 454 | - |
| Other current liabilities | 10 | 8163 | 1311 |
| Total current liabilities |  | 20993 | 12792 |
| **Long term liabilities** |  |  |  |
| Long term debt | 9 | 629 | - |
| Operating long-term lease liabilities | 7 | 700 | - |
| Contingent consideration | 11 | 5000 | - |
| Other long-term liabilities |  | 143 | - |
| **Total current and long-term liabilities** |  | 27465 | 12792 |
| **Stockholders' equity** | 12 |  |  |
| Preferred Stock, par value $0.00001; 10,000,000 authorized |  |  |  |
| Series A, Super Voting Preferred Stock - 20,000 shares (1,000 votes per share) issued and outstanding as of March 31, 2026, and December 31, 2025, respectively |  | - | - |
| Series B Convertible preferred stock, 107 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively |  | 7435 | 7435 |
| Series C Convertible preferred stock (to be issued) |  | 18000 | - |
| Common stock, par value $0.00001; 2,000,000,000 authorized, 1,846,424 and 142,426 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively |  | 11 | 11 |
| Non-controlling interest |  | (61) | (37) |
| Additional paid-in capital |  | 76651 | 45534 |
| Accumulated deficit |  | (49339) | (42999) |
| Total stockholders' equity |  | 52697 | 9944 |
| **Total liabilities and stockholders' equity** |  | $**80162** | $**22736** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**HEALTHCARE TRIANGLE, INC.**

**Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss** 

---

| | | | |
|:---|:---|:---|:---|
|  | | **Three Months Ended <br> March 31,** | **Three Months Ended <br> March 31,** |
|  | <br>**Note** | **2026** | **2025** |
| **Net revenue** |  | $9855 | $3704 |
| **Cost of revenue (exclusive of depreciation and amortization, shown separately below)** |  | 7462 | 3375 |
| **Gross margin** |  | **2393** | **329** |
| **Operating expenses** |  |  |  |
| &nbsp;&nbsp;&nbsp;Sales and marketing |  | 1779 | 373 |
| &nbsp;&nbsp;&nbsp;General and administrative |  | 3217 | 1198 |
| &nbsp;&nbsp;&nbsp;Research and development |  | 85 | 144 |
| &nbsp;&nbsp;&nbsp;Bad debt expense |  | 125 | - |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 56 | 810 | 12 |
| *Total operating expenses* |  | *6016* | *1727* |
| **Loss from operations** |  | (3623) | (1398) |
| &nbsp;&nbsp;&nbsp;Other income |  | 8 | 111 |
| &nbsp;&nbsp;&nbsp;Changes in fair value | 9 | (2435) | - |
| &nbsp;&nbsp;&nbsp;Interest expense |  | (85) | (413) |
| &nbsp;&nbsp;&nbsp;Forex loss |  | (63) | - |
| **Loss before income tax** |  | (6198) | (1700) |
| &nbsp;&nbsp;&nbsp;Provision for income tax |  | - | - |
| **Net loss** |  | $(6198) | $(1700) |
| **Other comprehensive income (OCI)** |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation loss |  | (166) | - |
| **Comprehensive loss** |  | **(6364)** | **(1700)** |
| **Comprehensive loss attributable to:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Stockholders |  | (6340) | (1700) |
| &nbsp;&nbsp;&nbsp;Non-controlling interest |  | (24) | - |
| Net loss per common share - basic and diluted, attributable to: |  |  |  |
| &nbsp;&nbsp;&nbsp;Stockholders | 16 | (6.81) | (0.17) |
| &nbsp;&nbsp;&nbsp;Non-controlling interest | 16 | (0.03) | - |
| &nbsp;&nbsp;&nbsp;Weighted average shares outstanding used in per common share computations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted |  | 930672 | 659 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**HEALTHCARE TRIANGLE, INC.**

**Unaudited Condensed Consolidated Statements of Changes in Stockholder's Equity**

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred stock<br> (Series A)** | **Preferred stock<br> (Series A)** | **Preferred stock<br> (Series B)** | **Preferred stock<br> (Series B)** | **Preferred stock<br> (Series C, to be issued)** | **Preferred stock<br> (Series C, to be issued)** | **Common stock** | **Common stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional paid-in**<br>**capital** | **Non-controlling**<br>**interest** | **Accumulated**<br>**deficit** | **Total stockholders'**<br>**equity** |
| **Three months ended March 31, 2026** | | | | | | | | | | | | |
| **Balance at December 31, 2025** | 20000 |  | 107 | 7435 |  | - | 142426 | 11 | 45534 | (37) | (42999) | 9944 |
| Net loss |  |  |  | - |  | - |  | - | - | (24) | (6174) | (6198) |
| Effects of exchange translation reserve (OCI) |  |  |  | - |  | - |  | - | - | - | (166) | (166) |
| Common stock and pre-funded warrants issued for acquisition |  |  |  | - |  | - | 55682<sup>(\*)</sup> | - | 12000 | - | - | 12000 |
| Preferred stock to be issued for acquisition |  |  |  | - |  | 18000 |  | - | - | - | - | 18000 |
| Common stock issued for cash | - |  | - | - |  | - | 515326 | - | 5387 | - | - | 5387 |
| Conversion of debt to equity | - |  | - | - |  | - | 451437 | - | 10167 | - | - | 10167 |
| Equity issued pursuant to a financing arrangement |  |  |  | - |  | - | 681553 | - | 3563 | - | - | 3563 |
| **Balance at March 31, 2026** | 20000 |  | 107 | 7435 |  | 18000 | 1846424 | 11 | 76651 | (61) | (49339) | 52697 |

---

(\*) See note 5(B) for details on common stock and pre-funded warrants issued in connection with the acquisition.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred stock (Series A)** | **Preferred stock (Series A)** | **Preferred stock (Series B)** | **Preferred stock (Series B)** | **Common stock** | **Common stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional <br> paid-in**<br>**capital** | **Accumulated**<br>**deficit** | **Total stockholders'**<br>**equity (deficit)** |
| **Three months ended March 31, 2025** | | | | | | | | | |
| **Balance at December 31, 2024** | **6000** | $**-**  | **107** | $**7435** | **380** |  | $**21022** | $**(33571)** | $**(5114)** |
| Net loss | **-** | **-**  | **-** | **-**  | **-** |  | - | (1700) | **(1700)** |
| Shares issued for services | 14000 | **-**  | **-** | **-**  | 9 |  | 88 | **-**  | **88** |
| Common Stock issued for cash | **-** | **-**  | **-** | **-**  | 470 |  | 95 | **-**  | **95** |
| Prefunded warrants issued for cash <sup>(1)</sup> | **-** | **-**  | **-** | **-**  |  |  | 395 | **-**  | **395** |
| Series B (cashless warrants) <sup>(2)</sup> | **-**  | **-**  | **-**  | **-**  |  |  | 14710 | - | **14710** |
| Expenses relating to funding | **-** | **-**  | **-** | **-**  |  |  | (1524) | **-**  | **(1524)** |
| Conversion of Debt to Equity | **-**  | **-**  | **-** | **-**  | 176 |  | 1191 | **-**  | **1191** |
| Shares issued for acquisition (Contingent Consideration) |  |  |  |  | 40 |  | 400 | **-**  | **400** |
| Issue of Options (ISO/NSO) | **-** | **-**  | **-** | **-**  | **-** |  | 36 | **-**  | **36** |
| **Balance at March 31, 2025** | **20000** | $**-**  | **107** | $**7435** | **1075** |  | $**36413** | $**(35271)** | $**8577** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**HEALTHCARE TRIANGLE, INC.**

**Unaudited Condensed Consolidated Statements of Cash Flows**

---

| | | | |
|:---|:---|:---|:---|
|  | | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** |
|  |<br>**Note** | **2026** | **2025** |
|  | | **(In '000)** | |
| **Cash flows from operating activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net loss |  | $(6198) | $(1700) |
| Adjustment to reconcile net loss to net cash provided by / (used in) operating activities |  |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization |  | 810 | 12 |
| &nbsp;&nbsp;&nbsp;Change in fair value |  | 2435 | - |
| &nbsp;&nbsp;&nbsp;Common stock issued for services |  | - | 88 |
| &nbsp;&nbsp;&nbsp;Amortization of debt discount |  | - | 223 |
| &nbsp;&nbsp;&nbsp;Other income |  | - | (110) |
| &nbsp;&nbsp;&nbsp;Stock compensation expenses |  | - | 36 |
| &nbsp;&nbsp;&nbsp;Interest expenses |  | 89 | - |
| &nbsp;&nbsp;&nbsp;Interest expenses settled by equity |  | - | 316 |
| &nbsp;&nbsp;&nbsp;Bad debt expense |  | 125 | - |
| Changes in working capital: |  |  |  |
| Increase in: |  |  |  |
| &nbsp;&nbsp;&nbsp;Accounts receivable |  | (1542) | (797) |
| &nbsp;&nbsp;&nbsp;Other current assets |  | (1284) | (785) |
| &nbsp;&nbsp;&nbsp;Due from affiliates |  | - | (1448) |
| &nbsp;&nbsp;&nbsp;Accounts payable |  | (280) | (820) |
| &nbsp;&nbsp;&nbsp;Other current liabilities |  | (1019) | (572) |
| *Net cash used in operating activities* |  | *(6864)* | *(5557)* |
| **Cash flows from investing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of furniture and equipment |  | (22) | - |
| &nbsp;&nbsp;&nbsp;Acquisition of Teyame | 5 | (6000) |  |
| *Net cash used in investing activities* |  | *(6022)* | *-*  |
| **Cash flows from financing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net proceeds from short-term borrowing | 9 | 548 | 186 |
| &nbsp;&nbsp;&nbsp;Net proceeds from long-term debt | 9 | 269 | - |
| &nbsp;&nbsp;&nbsp;Payment of lease liability | 7 | (137) | - |
| &nbsp;&nbsp;&nbsp;Repayment of convertible note |  | - | (1500) |
| &nbsp;&nbsp;&nbsp;Proceeds from equity issuance |  | 8881 | 13677 |
| &nbsp;&nbsp;&nbsp;Interest paid |  | (83) | - |
| *Net cash provided by financing activities* |  | *9478* | *12363* |
| Cumulative translation adjustment |  | 98 | *-*  |
| ***Net increase / (decrease) in cash and cash equivalents*** |  | ***(3310*** ***)*** | ***6806*** |
| **Cash and cash equivalents** |  |  |  |
| Cash and cash equivalents at the beginning of the year |  | 7625 | 20 |
| Cash and cash equivalents at the end of the period |  | $4315 | $6826 |
| **Supplementary disclosure of cash flows information** |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest |  | $- | $413 |
| &nbsp;&nbsp;&nbsp;Conversion of debt to equity |  | 10165 | 1191 |
| &nbsp;&nbsp;&nbsp;Acquisition of Teyame (see note 5[B] for details) |  | $41000 | $- |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**1) Basis of Preparation of Unaudited Condensed Consolidated Financial Statements**

These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission, or SEC, Regulation S-X. The December 31, 2025, consolidated balance sheet was derived from our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary to present fairly our financial position as of March 31, 2026, the results of operations, comprehensive loss, stockholders' deficit, and cash flows for the three months ended March 31, 2026 and 2025. The results of operations for the periods presented are not necessarily indicative of the results to be expected for any future period. The information contained herein should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC. Management considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these condensed consolidated financial statements.

All intercompany balances and transactions have been eliminated upon consolidation.

Certain balances from the prior fiscal year have been reclassified to conform to the current period presentation.

**Organization and Description of Business**

Healthcare Triangle Inc. ("HTI" or "the Company") was incorporated under the laws of the State of Nevada on October 29, 2019, and then converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences ('HCLS") industry. On January 1, 2020, the Company acquired the Life Sciences Business of SecureKloud Technologies Inc. and on May 8, 2020, the Company acquired Cornerstone Advisors Group LLC (Healthcare Business) from SecureKloud.

Effective January 1, 2026, the Company, through its wholly owned subsidiaries, Teyame 360 S.L. ("Teyame") and Datono Mediacion S.L. ("Datono") (see note 5[B] for details), operate together as an integrated platform providing AI-powered omnichannel customer experience, marketing, and financial/insurance distribution services.

Teyame leverages its technology solutions to provide customer engagement services that combine artificial intelligence, telemarketing, and contact center operations to support customer acquisition, retention, and service. Its platform enables enterprises particularly in financial services, insurance, and healthcare to manage end-to-end customer interactions across multiple channels.

Datono complements this platform as an insurance brokerage entity, facilitating the marketing and sales of insurance products. Together, the companies form a vertically integrated model combining customer acquisition technology with distribution capabilities, particularly in regulated sectors such as insurance.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**Liquidity Risk**

The Company incurred loss from operations of $3,623, had negative operating cash flows of $6,864, and accumulated deficits of $49,339 for the quarter ended March 31, 2026. Management evaluated these conditions and concluded that they have been sufficiently mitigated by the Company's net assets of $52,697 (including cash and cash equivalents of $4,315) at March 31, 2026, and gross proceeds of $484 raised through equity issuance subsequent to the quarter-end. Accordingly, management has concluded that the Company has sufficient resources to fund operations and meet its obligations as they become due for a period of at least twelve months from the date these unaudited condensed consolidated financial statements are issued.

**2) Summary of Significant Accounting Policies**

**Revenue Recognition**

We recognize revenues as we transfer control of deliverables (services, solutions, and platform) to our clients in an amount reflecting the consideration to which we expect to be entitled. To recognize revenues, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenues when a performance obligation is satisfied. We account for a contract when it has approval and commitment from all parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We apply judgment in determining the customer's ability and intention to pay based on factors including historical payment experience, credit profile, and geographic and industry risk factors. For customers acquired through business combinations, collectability is assessed using the acquired entity's collection history with those customers, supplemented by post-acquisition payment performance. A contract is recognized only where collectability of substantially all consideration is probable.

For performance obligations where control is transferred over time, revenues are recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the deliverables to be provided.

The Company accounts for revenue from a contract after it is approved by the customer, and after ensuring that the rights of each party regarding the services to be transferred, the payment terms, the commercial substance, and the collectability is ascertained. In assessing collectability, the company applies judgment and considers factors such as the customer's credit profile, past payment behavior, and the nature and geography of the customer relationship

Contract modifications, such as changes in scope, rates, or duration, are assessed to determine whether they should be accounted for as a separate contract or as part of the existing contract. A modification is treated as a separate contract when it adds services at a price that reflects their standalone selling price. Otherwise, the modification is combined with the existing contract, and the transaction price is updated on a prospective or cumulative catch-up basis, as appropriate.

When it becomes probable that total costs to satisfy a contract will exceed the transaction price, the expected loss is recognized in full in the period in which the loss becomes probable and can be reasonably estimated, regardless of whether work has commenced under the contract.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

Revenue is earned and recognized in the following segments:

**A. Software Services**

The Company enters into contractual obligations with the customers to perform (i) Strategic advisory services which include assessment of the enterprise network, applications environment and advise on the design and tools; (ii) Implementation services which include deployment, upgrades, enhancements, migration, training, documentation and maintenance of various electronic health record systems and (iii) Development services which include customization of network and applications in the public cloud environment.

Revenue from Strategic advisory, Implementation and Development services are distinct performance obligation and is recognized on time-and-material or fixed-price project basis. Revenues related to time-and-material are recognized over the period the services are provided using labor hours. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract's total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized immediately, where appropriate.

We may enter into contracts that consist of multiple performance obligations. Such contracts may include any combination of our deliverables. To the extent a contract includes multiple promised deliverables, we apply judgment to determine whether promised deliverables are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised deliverables are accounted for as a combined performance obligation. For contracts with multiple distinct performance obligations, we allocate consideration among the performance obligations based on their relative standalone selling price. Standalone selling price is the price at which we would sell a promised good or service separately to the customer. When not directly observable, we estimate standalone selling price by using the expected cost plus a margin approach. We establish a standalone selling price range for our deliverables, which is reassessed on a periodic basis or when facts and circumstances change.

Contract modifications, such as extensions of statement of work duration or changes in resources and rates, are evaluated under ASC 606 and accounted for prospectively as a separate contract or modification of the existing contract, based on whether the modification adds distinct performance obligations at standalone selling prices.

When the estimated costs to complete a performance obligation exceed the expected transaction price, the full amount of the anticipated loss is recognized immediately in the period in which the loss becomes probable and estimable.

Certain contracts include variable consideration such as rate adjustments, which is estimated using the most likely amount method and included in the transaction price only to the extent that a significant revenue reversal is not probable. Estimates are reassessed at each reporting date.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**B. Managed Services and Support**

The Company has standard contracts for its Managed Services and Support, however the statement of work contained in such contracts is unique for each customer. A typical Managed Services and Support contract would provide for some or all of the following types of services being provided to the customer: Cloud hosting, Continuous monitoring of applications, security and compliance and support.

Revenue from Managed services and support is a distinct performance obligation and recognized based on Standalone Selling Price (SSP), ratably on a straight-line basis over the period in which the services are rendered. Contract with customers includes subcontractor services or third-party cloud infrastructure services in certain integrated services arrangements. In these types of arrangements, revenue is recognized net of costs when the Company is acting as an agent between the customer and the vendor, and gross when the Company is the principal for the transaction. In doing so, the Company first evaluates whether it controls the platform or service before it is transferred to the customer. The Company considers whether it has the primary obligation to fulfil the contract, pricing discretion and other factors to determine whether it controls the platform or service and therefore is acting as principal or agent.

**C. Customer Engagement Services**

The Customer Engagement Services segment includes services rendered to financial institutions in connection with the promotion and distribution of banking and credit products; services provided as an external collaborator to insurance intermediaries in the distribution of insurance products; outbound and inbound telemarketing; customer acquisition campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services that support customers' digital customer-acquisition and customer-care strategies.

Under these arrangements, the company typically acts as an intermediary or service provider, identifying and contacting potential customers or insureds, explaining product features, collecting and submitting applications or leads, and performing related administrative tasks and customer-care activities in accordance with the instructions, scripts and quality standards agreed with each customer. Consideration may be in the form of commissions based on approved and issued banking or credit products or concluded or renewed insurance policies, or service fees based on time-and-effort, unit-based pricing, fixed price per completed output, or milestone-based pricing, as specified in the contract.

Commission revenue is recognized when the company's services under the relevant transaction have been performed and the specified conditions have been met under the contract. Revenue from time-based or unit-based services is recognized as the underlying services are performed and the corresponding measurable outputs are delivered in accordance with the contract. Revenue under fixed-price or milestone-based arrangements is recognized over time as the related services are performed and contractual milestones are achieved.

**D. Corporate and Others**

This segment includes Platform Services revenue, alongside unallocated corporate head office costs. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

The revenue from Platform Services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform Services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract's total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.

Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers' systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.

**Fair Value Measurements**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
|  | **Fair Value Measured Using** | **Fair Value Measured Using** | **Fair Value Measured Using** | **Fair Value Measured Using** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| *Financial Assets:* |  |  |  |  |
| Cash and cash equivalents | $4315 |  |  | $4315 |
| *Financial liabilities:* |  |  |  |  |
| 2025 Convertible Notes<sup>(\*)</sup> (refer note 9[B]) |  |  | $1141 | $1141 |
| Operating lease liabilities |  |  | $1154 | $1154 |
| Debt with credit institutions | $8467 |  |  | $8467 |

---

<sup>(\*)</sup> 2025 Convertible Notes is part of short-term borrowing.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | **Fair Value Measured Using** | **Fair Value Measured Using** | **Fair Value Measured Using** | **Fair Value Measured Using** | **Fair Value Measured Using** |
|  | **Level 1** | **Level 2** | **Level 3** |  | **Total** |
| *Financial Assets:* |  |  |  |  |  |
| Cash and cash equivalents | $7625 |  |  |  | $7625 |
| *Financial liabilities:* |  |  |  |  |  |
| 2025 Convertible Notes (refer note 9[B]) | $— | $— | $10543 | \*\* | $10543 |

---

<sup>(\*\*)</sup> Corresponding figures have been rearranged for the purposes of comparison.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**Concentration**

The Company monitors the credit worthiness of its customers through various factors, including review of their financial statements and other associated information. For the quarters ended March 31, 2026, and 2025, sales to five major customers accounted for approximately 49% and 57% of total revenue respectively. For the quarters ended March 31, 2026, and 2025, accounts receivable from five major customers accounted for approximately 57% and 59% of the total accounts receivable.

As of March 31, 2026, and December 31, 2025, the Company had $3,129 and $6,503 respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.

**3) Accounts Receivable, net**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Accounts receivable, gross | $8694 | $2272 |
| Less: Allowance for doubtful accounts (current expected credit loss) | (327) | (202) |
| Accounts receivable, net | $8367 | $2070 |

---

As at March 31, 2026, the Company remeasured its allowance for current expected credit loss to $327, showing a net increase of $125 from the balance as at December 31, 2025.

**Current Expected Credit Loss movement\*:**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Opening balance | $202 | $185 |
| Provision for the period / year | 125 | 17 |
| **Closing balance** | $**327** | $**202** |

---

\* During the quarter ended March 31, 2026, and year ended December 31, 2025, the Company collected nil and $117 respectively.

**4) Other current assets**

---

| | | |
|:---|:---|:---|
|  | **March 31, <br> 2026** | **December 31, <br> 2025** |
| Prepaid expenses | $519 | $267 |
| Advance to acquire Teyame (see note 5[B] for details) | - | 3000 |
| Receivable from Spartan Capital (see note 12[D] for equity financing details) | 914 | - |
| Unbilled revenue | 542 | 3 \* |
| Others | 412 | 186 \* |
| **Total** | $**2387** | $**3456** |

---

\* Corresponding figures have been rearranged for the purposes of comparison.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**5) Goodwill and Other Intangible Assets**

---

| | | | |
|:---|:---|:---|:---|
| | | **March 31, <br> 2026** | **December 31, <br> 2025** |
| Goodwill | (see 'A' below) | $2946 | $2946 |
| Other intangible assets, net | (see 'B and C' below) | $55219 | $2808 |

---

&nbsp;&nbsp;&nbsp;&nbsp;A) On June 16, 2025 (the "Closing
 date"), Healthcare Triangle, Inc. through its wholly owned subsidiary Quantum Nexus Inc. (the "Company") and Niyama
 Healthcare, Inc., a Delaware corporation, a provider of Mental Health and Hospital Information Systems technology, across India, South
 East Asia, and Europe (the "Seller") entered into an Asset and Stock Transfer Agreement (ATA). Pursuant to the ATA, the
 Company agreed to purchase the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) 100%
 shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - Hospital Information Systems SaaS Provider (the "Transferred
 Equity"), as a whole and as a going concern in exchange for the Purchase Price, which comprised the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) $1,494 in cash, (2) $4,601 in equity consideration; and (3) up to $1,200 (having a fair value of nil as of March 31, 2026, and December 31, 2025) in earn-out payments contingent on first-year financial performance targets to be agreed mutually.

The transaction resulted in recognition of goodwill with a carrying value of $2,946, as of March 31, 2026, and December 31, 2025. There are no impairment indicators as at March 31, 2026, and December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B) On January 22,
 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. ("Teyame") and Datono
 Mediacion S.L. ("Datono") through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate
 purchase price for the Acquired Companies is up to $50,000,
 subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash payout of $15,000,
 with the balance settled through issuance of a combination of the Company's common stock, preferred stock, with an additional earnout
 component payable in the Company's preferred stock upon achievement of specified post-closing performance targets.

The cash consideration includes: (i) $3,000 paid during 2025 pursuant to an advance agreement dated December 3, 2025, (ii) $6,000 paid during January, 2026 (iii) $3,200 paid on April 20, 2026, and (iv) $2,800 payable on the earlier of the conditions being met as outlined in the Share Purchase Agreement, or six months from the date of the Share Purchase Agreement (but in no event prior to April 29, 2026).

The equity consideration includes (a) restricted shares or pre-funded warrants of the Company's common stock with an agreed value of $12,000 and (b) a series of the Company's preferred stock with an agreed value of $18,000 that is convertible into the Company's common stock, subject to Shareholders' approval. As of March 31, 2026, 55,482 restricted shares of common stock and 424,856 pre-funded warrants convertible to common stocks were issued towards the $12,000 common stock issuance, whereas preferred stocks are yet to be issued. The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, are determined by reference to a "Base Price" equal to the average of the volume-weighted average prices ("**VWAPs**") of the Company's common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stock is not convertible into common stock until applicable shareholder approval is obtained as contemplated by the Share Purchase Agreement. The Share Purchase Agreement also includes a mechanism intended to limit issuance in excess of 19.99% of the Company's outstanding common stock immediately prior to issuance, including the issuance of a pre-funded warrant for any excess shares in lieu of issuing shares in excess of such limitation at closing, and provides that the pre-funded warrant would have a nominal exercise price and be exercisable on a cashless basis, subject to the terms of the Share Purchase Agreement.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

The Share Purchase Agreement also provides for an earnout payable in the Company's Series C preferred stock to certain key management employees of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement.

---

| | |
|:---|:---|
| **Purchase consideration** | **Amount** |
| Cash paid | $9000 |
| Purchase consideration payable | $6000 |
| Issuance of common stock | $12000 |
| Issuance of preferred stock | $18000 |
| Earnout consideration payable | $5000 |
| **Total** | $**50000** |

---

The Company is in the process of determining the fair values of the identifiable assets acquired and liabilities assumed as of the acquisition date in accordance with ASC 805, Business Combinations. As the initial accounting for the business combination is incomplete as of the date of these financial statements, the Company has not yet finalized the purchase price allocation. The provisional amounts recognized reflect management's best estimates based on information available at this time. The final purchase price allocation, including the determination of fair values of identifiable intangible assets, property and equipment, deferred tax assets and liabilities, and any resulting goodwill, will be completed as soon as practicable and within the measurement period of up to one year from the acquisition date as permitted under ASC 805-10-25-15. Any adjustments to the provisional amounts identified during the measurement period will be recognized in the reporting period in which the adjustment is determined, with a corresponding adjustment to goodwill.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C) Other intangible assets**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  |<br>**Useful**<br>**life**<br>**(Years)** | **Gross**<br>**Carrying**<br>**Amount** | **Amortization**<br>**expense for**<br>**the period** |<br>**Accumulated**<br>**Amortization** | **Net**<br>**Carrying**<br>**Amount** | **Gross**<br>**Carrying**<br>**Amount** |<br>**Accumulated**<br>**Amortization** | **Net**<br>**Carrying**<br>**Amount** |
| Intellectual property | **3** | $3402 | $301 | $962 | $2440 | $3402 | $660 | $2742 |
| Trademark | **3** | 81 | &nbsp;&nbsp;&nbsp;&nbsp; 5 | 21 | 60 | 81 | 15 | 66 |
| Software | **3** | 450 \* | 2 | 436 | 14 | 35 | 35 |  |
| Technology platform | **3 - 4** | 7123 \* | 197 | 4418 | 2705 | - | - | - |
| **Intangible assets, total** |  | $**11056** | $**505** | $**5837** | $**5219** | $**3518** | $**710** | **2808** |

---

\* The Company acquired Software and Technology platform as part of the business combination effective January 1, 2026. See note 5(B) for details.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**6) Furniture and Equipment**

Furniture and equipment consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Furniture and equipment, at cost | $5298 | $67 |
| Less: Accumulated depreciation | (3968) | (62) |
| Furniture and equipment, net | $1330 | $5 |

---

During the quarter ended March 31, 2026, the Company purchased furniture and equipment amounting to $22. In addition, the Company acquired furniture and equipment with a cost of $5,209 and accumulated depreciation of $3,742 as part of the business combination (see note 5[B] for details). Depreciation expenses for the quarters ended March 31, 2026, and 2025 were $163 and $12 respectively. There were no disposals during the current or prior periods presented.

**7) Right-of-use Assets**

The Company determines if an arrangement contains a lease at inception. Right-of-use ("ROU") assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

The Company utilized a portfolio approach in determining the discount rate. The portfolio approach takes into consideration the range of the term, the range of the lease payments, the category of the underlying asset and the Company's estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company also considered its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating the incremental borrowing rates.

Leases with a term of 12 months or less are not recorded on the balance sheet, per the election of the practical expedient noted above. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company recognizes variable lease payments in the period in which the obligation for those payments is incurred. Variable lease payments that depend on an index or a rate are initially measured using the index or rate at the commencement date, otherwise variable lease payments are recognized in the period incurred.

The Company's principal facility is located in Pleasanton, CA. Lease rental for the quarter ended March 31, 2026, was $19 and whereas rent expenses for the quarter ended March 31, 2025 were $43. Depreciation expense for the ROU asset for the quarter ended March 31, 2026 was $5.

In addition, the Company acquired right-of-use assets and lease liability as part of the business combination (see note 5[B] for details). The Company acquired right-of-use assets with a cost of $3,879 and accumulated depreciation of $2,747 as part of the business combination (see note 5[B] for details). The lease relates to an office building located at Calle Rufino González 21, 28037 Madrid and a vehicle. The lease terms are 84 months for the building and 48 months for the vehicle. The leases were measured using discount rates of 1.50% for building and 6.99% for vehicle, resulting in lease liabilities of **$**3,823 and $64, respectively as of March 31, 2026. Lease rental and depreciation expense for the quarter ended March 31, 2026, were $114 and $137 respectively.

**ROU Asset:**

---

| | | | |
|:---|:---|:---|:---|
|  | **March 31,<br> 2026** |  | **December 31, <br> 2025** |
| Operating right-of-use assets, at cost | $4401 | \* | $&nbsp;&nbsp;&nbsp;&nbsp; - |
| Less: Accumulated depreciation | (3235 |)\* | - |
| Operating right-of-use assets, net | $1166 |  | $- |

---

\* Includes operating right-of-use assets acquired as part of business combination as explained in the note above.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**Lease liability:**

Future minimum lease obligations under our non-cancellable lease agreement as of March 31, 2026, are as follows:

---

| | |
|:---|:---|
| **Fiscal Year** | **Total** |
| 2026 | $603 |
| 2027 | 526 |
| 2028 | 76 |
| 2029 | 13 |
| **Total** | **1218** |
| Less: Imputed interest | (64) |
| **Present value of net future minimum lease payments** | **1154** |
| Less: Operating lease liability, current | (454) |
| Operating lease liability, non-current | $**700** |

---

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Operating lease liability, current | $454 |  |
| Operating lease liability, non-current | $700 |  |

---

**8) Advances**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Advance to related party contractor - for AI tools and software development | $3200 | $3200 |
| Advance to related party contractor - for services | 626 | 626 |
| **Total Advances** | $**3826** | $**3826** |

---

The balance outstanding from SecureKloud Technologies Limited as of March 31, 2026, and December 31, 2025, is $3,826. The balance is unsecured, non-interest bearing and is expected to be settled in the ordinary course of business, as outlined below:

$3,200 was advanced in connection with the design, develop and deliver an Integrated Health Advisory & Care Platform & Tools including certain artificial intelligence-enabled software tools and related intellectual property, intended to support the Company's current and future product offerings at a cost not-to-exceed $3,200, and

$626 for provision of certain services to the Company. These advances are expected to be settled in the ordinary course of business.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Related party transactions:** 

Following are the transactions with related parties during the periods presented:

---

| | | | |
|:---|:---|:---|:---|
| **Related Parties** | **Nature of transactions** | **Quarter <br> ended <br> March 31, <br> 2026** | **Quarter <br> ended <br> March 31, 2025** |
| SecureKloud Technologies Limited, India | Services received | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 539 | $912 |
|  | Amounts advanced | - | 1298 |
| SecureKloud Technologies, Inc. | Services received | - | 221 |
|  | Amounts advanced | - | 785 |
|  | Services rendered | - | 138 |
|  | Amounts collected by related party on behalf of the Company | - | 305 |
|  | Rent expenses paid | - | 43 |
| Blockedge Technologies, Inc. | Services received | 60 |  |
|  | Amounts advanced | - | 54 |
| Key management personnel | Remuneration | 235 | 400 |
| Board of Directors | Compensation | $55 | $55 |

---

**9) Short-Term Borrowing**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Recourse financing [refer (A) below] | $24 | $161 |
| Convertible notes [refer (B) below] | 1141 | 10543 |
| Debt with credit institutions – current [refer (C) below] | 7838 |  |
| Others | 85 | 33 |
| **Total** | $**9088** | $**10737** |

---

**A. Recourse Financing**

During 2022, the Company obtained a credit facility from Seacoast Business Funding (SBF), a division of Seacoast National Bank. The funding is against the accounts receivable of the Company and one of its subsidiaries. The maximum amount of advance under the arrangement is $10,000 and the bank may advance upto 90% of the unpaid domestic outstanding accounts under the recourse agreement.

The SBF facility incurred a factoring interest cost of 8.5% during the quarter ended March 31, 2026, amounting to $10 and 8.5% for the quarter ended March 31, 2025, amounting to $16. The gross receivables against which advances were received from such arrangement as at March 31, 2026, and December 31, 2025, were $2,463 and $2,225 respectively.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

The carrying amount of associated recourse financing liability was $24 and $161, as of March 31, 2026, and December 31, 2025, respectively.

In addition, a recently acquired subsidiary with an acquisition date of January 1, 2026, of the Company utilizes recourse-based accounts receivable financing arrangement with a number of banks, whereby the subsidiary receives cash against the customer invoices. Under this arrangement, the maximum advance amount available to the subsidiary is $4,038, subject to invoice ageing and related terms. As the arrangement is with recourse, the subsidiary retains the credit risk associated with the underlying receivables and accordingly continues to recognize the related accounts receivable on its balance sheet. Amounts advanced by the bank are recognized as current liability at fair value, which approximates the actual proceeds received due to the short-term nature of the advances, generally ranging from 60 to 120 days. Interest incurred on the advances is recognized as finance expense in the period incurred. Since the arrangement does not constitute a transfer of receivables under applicable accounting standards, no gain or loss is recognized on the transaction.

This facility incurred a factoring interest rate ranging from 2.77% to 3.52% during the quarter ended March 31, 2026, whereas the interest cost amounted to $31. The gross receivables against which advances were received from such arrangement as at March 31, 2026, was $6,170.

The carrying amount of associated recourse financing liability was $3,734 as at March 31, 2026.

**B. 2025 Convertible Notes**

The following table represents changes in the fair value of the 2025 Debentures for the periods presented:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Opening balance - fair value | $10543 | $12000 |
| Less: Debt repayment | (1670) |  |
| Less: Conversions to equity stock (fair value) | (10167) | (1416) |
| Changes in fair value (recognized in earnings) | 2435 | (41) |
| **Closing balance - fair value** | $**1141** | $**10543** |

---

As of March 31, 2026, the significant assumptions used by an independent third party valuer in the valuation included the Company's common stock price of $2.69 per share ($37.95 per share as of December 31, 2025), expected volatility of 87% (90.7% as of December 31, 2025), a risk-free rate of 3.5% (3.53% as of December 31, 2025), and a remaining contractual term of approximately 0.7 years (0.89 years as of December 31, 2025). The valuation also reflected assumptions regarding expected conversion behavior and settlement outcomes over the remaining life of the instruments. In addition, the model was calibrated to observed transaction proceeds. No financing below the contractual floor price is expected in 2026, and accordingly no floor-reset event was incorporated into the March 31, 2026, valuation.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**C. Debt from credit institutions**

Teyame and Datono have secured various credit facilities across multiple financial institutions. As of March 31, 2026, the total available credit facilities and loans amounted to $9,989, and the amount withdrawn and utilized as of that date was $8,467, of which $7,838 is due within a period of 12 months from the balance sheet date, whereas $629 is classified as long-term debt with maturity dates falling due beyond 1 year. These loans and facilities carry interest rates ranging from 1.3% - 5.24% and are obtained to cover the working capital and liquidity needs.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Credit<br> institution** | **Facility<br> type** | **Interest rate** | **Conditions** | **Maturity<br> date** | **As of<br> January 1, <br> 2026** | **Additions<br> during<br> the period** | **Repayments<br> during<br> the period** | **As of<br> March 31,<br> 2026** | **Short<br> term** | **Long<br> term** |
| Caixabank | Working capital | 1.30% | &nbsp;&nbsp;Fixed rate | &nbsp;&nbsp;10/26/2026 |  | 1503 | (1341) | 162 | 162 |  |
| Bankinter | " | 5.24% | &nbsp;&nbsp;Eur 12m + 2.50% | &nbsp;&nbsp;7/23/2026 |  |  |  |  |  |  |
| Banco Santander | " | 4.71% | &nbsp;&nbsp;Eur 6m + 2.25% | &nbsp;&nbsp;5/13/2026 |  | 4950 | (4615) | 335 | 335 |  |
| BBVA | " | 3.56% | &nbsp;&nbsp;Eur 3m + 1.40% | &nbsp;&nbsp;10/5/2026 | (1) | 3796 | (3511) | 284 | 284 |  |
| BBVA Click & Pay | " | 3.96% | &nbsp;&nbsp;Eur 6m + 1.5% | &nbsp;&nbsp;6/21/2026 | 252 | 28 |  | 280 | 280 |  |
| Caixabank | " | 4.24% | &nbsp;&nbsp;Eur 12m + 1.50% | &nbsp;&nbsp;11/27/2026 | (5) | 5784 | (5486) | 293 | 293 |  |
| Abanca | " | 1.80% | &nbsp;&nbsp;Fixed rate | &nbsp;&nbsp;7/5/2027 | 222 | 488 | (480) | 230 |  | 230 |
| Unicaja | " | 3.56% | &nbsp;&nbsp;Eur 3m + 1.40% | &nbsp;&nbsp;6/24/2026 |  | 346 | (116) | 230 | 230 |  |
| Ibercaja Multiproducto Multiempresa | " | 3.71% | &nbsp;&nbsp;Eur 6m + 1.25% | &nbsp;&nbsp;3/15/2027 | 443 | 444 | (427) | 460 | 460 |  |
| Targobank | " | 1.51% | &nbsp;&nbsp;Fixed rate | &nbsp;&nbsp;5/29/2026 | 38 |  | (19) | 19 | 19 |  |
| Deutsche | " | 4.24% | &nbsp;&nbsp;Eur 12m + 1.50% | &nbsp;&nbsp;9/5/2027 |  | 2471 | (2299) | 172 |  | 172 |
| Bankia | Long term | 1.50% | &nbsp;&nbsp;Fixed rate | &nbsp;&nbsp;4/27/2026 | 20 |  | (15) | 5 | 5 |  |
| Bsabadell | " | 4.80% | &nbsp;&nbsp;Eur 12m + 1.10% | &nbsp;&nbsp;4/29/2028 | 239 |  | (25) | 214 | 101 | 113 |
| Bankinter | Working capital | 3.41% | &nbsp;&nbsp;Eur 3m + 1.25% | &nbsp;&nbsp;7/23/2026 | 180 | 67 | (135) | 112 | 112 |  |
| Caixabank | " | 3.36% | &nbsp;&nbsp;Eur 3m + 1.20% | &nbsp;&nbsp;10/22/2026 | 805 | 805 | (805) | 805 | 805 |  |
| Deutsche | " | 3.95% | &nbsp;&nbsp;Eur 6m + 1.50% | &nbsp;&nbsp;7/4/2029 | 1267 | 848 | (959) | 1156 | 1156 |  |
| Ibercaja Multiproducto Multiempresa | " | 3.56% | &nbsp;&nbsp;Eur 3m + 1.25% | &nbsp;&nbsp;3/15/2027 | 62 | 31 |  | 93 | 93 |  |
| Abanca | " | 4.01% | &nbsp;&nbsp;Eur 3m + 1.85% | &nbsp;&nbsp;6/20/2026 | 230 | 287 | (230) | 287 | 287 |  |
| Caixabank | " | 1.30% | &nbsp;&nbsp;Fixed rate | &nbsp;&nbsp;10/26/2026 |  | 2701 | (2476) | 225 | 225 |  |
| Bankinter | " | 5.24% | &nbsp;&nbsp;Eur 12m + 2.50% | &nbsp;&nbsp;7/23/2026 |  | 116 | (116) |  |  |  |
| Bankinter Línea Pago Impuestos | " | 1.1 trim.% | &nbsp;&nbsp;One-time fee of 1.1% for 3 months | &nbsp;&nbsp;7/23/2026 | 115 |  | (115) |  |  |  |
| Banco Santander | " | 4.32% | &nbsp;&nbsp;Eur 6m + 1.86% | &nbsp;&nbsp;5/11/2026 |  | 1550 | (949) | 601 | 601 |  |
| BBVA | " | 3.56% | &nbsp;&nbsp;Eur 3m + 1.40% | &nbsp;&nbsp;10/5/2026 | (2) | 3032 | (2745) | 285 | 285 |  |
| BBVA Click & Pay | " | 3.96% | &nbsp;&nbsp;Eur 6m + 1.5% | &nbsp;&nbsp;6/21/2026 | 287 | 161 | (167) | 281 | 281 |  |
| Caixabank | " | 4.24% | &nbsp;&nbsp;Eur 12m + 1.50% | &nbsp;&nbsp;11/27/2026 | (2) | 4055 | (3963) | 90 | 90 |  |
| Ibercaja | " | 3.56% | &nbsp;&nbsp;Eur 3m + 1.25% | &nbsp;&nbsp;3/15/2027 | 124 | 653 | (605) | 172 | 172 |  |
| Deutsche | " | 4.24% | &nbsp;&nbsp;Eur 12m + 1.50% | &nbsp;&nbsp;9/5/2027 |  | 1697 | (1583) | 114 |  | 114 |
| BBVA | Long term | 4.60% | &nbsp;&nbsp;Eur 12m + 2.50% | &nbsp;&nbsp;4/27/2026 | 32 |  | (24) | 8 | 8 |  |
| Deutsche | " | 3.85% | &nbsp;&nbsp;Eur 12m + 1.65% | &nbsp;&nbsp;11/23/2026 | 80 |  | (22) | 58 | 58 |  |
| Caixabank | Working capital | 3.36% | &nbsp;&nbsp;Eur 3m + 1.20% | &nbsp;&nbsp;10/22/2026 | 1265 | 1266 | (1265) | 1266 | 1266 |  |
| Deutsche | " | 3.95% | &nbsp;&nbsp;Eur 6m + 1.50% | &nbsp;&nbsp;7/4/2029 | 230 | 345 | (345) | 230 | 230 |  |
| Ibercaja multipruducto | " |  |  |  | 21 | - | (21) | - | - | - |
|  |  |  |  |  | **5902** | **37424** | **(34859)** | **8467** | **7838** | **629** |

---

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

---

| | |
|:---|:---|
| **Fiscal Year** | **As of<br> March 31,<br> 2026** |
| 2026 | $7838 |
| 2027 | $620 |
| 2028 | $9 |

---

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31, <br> 2025** |
| Current | 7838 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - |
| Non-current | 629 | - |
| **Total** | $**8467** | $**-**  |

---

The debt with credit institutions was acquired as part of the Teyame and Datono business combination on January 1, 2026, and represents liabilities assumed at the acquisition date. No new facilities have been entered into by the consolidated group subsequent to the acquisition date during the quarter ended March 31, 2026.

**10) Other current liability**

---

| | | |
|:---|:---|:---|
| **Particulars** | **March 31, <br> 2026** | **December 31, <br> 2025** |
| Accrued payroll | $202 | $216 |
| Purchase consideration payable (refer note 5[B]) | 6000 | - |
| Insurance | - | 179 |
| Milestone deposit | 249 | 97 |
| Director's fees | 55 | 55 |
| Professional fees payable | 545 | - |
| Commission accrual | 411 | 411 |
| Accrued liability | 270 | - |
| Other | 431 | 353 \* |
| **Total** | $**8163** | $**1311** |

---

\* Corresponding figures have been rearranged for the purposes of comparison.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**11) Contingent consideration** 

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. ("Teyame") and Datono Mediacion S.L. ("Datono") through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash component and equity component, with an additional earnout component payable in the Company's preferred stock upon achievement of specified post-closing performance targets. The Share Purchase Agreement also provides for an earnout payable in the Company's preferred stock to certain key management employees of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement. See note 5(B) for details.

**12) Stockholder Equity** 

All references to the number of common shares and price per Common Stock, for all periods presented, have been adjusted to reflect the following:

- one-for-sixty reverse stock split effective February 10, 2026.

These reverse splits reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. The basic and diluted earnings consider the effect of reverse split across the reporting periods.

Accordingly, unless indicated otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the Reverse Stock Split. There was no change to the shares authorized or in the par value per share of common stock of $0.00001.

The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder's percentage interest in the Company's equity. The Company issued fractional shares at the participant level in connection with the Reverse Stock Split.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**A. Common Stock**

i. Equity Issuance and Pre-Funded Warrants for Business Combination

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. ("Teyame") and Datono Mediacion S.L. ("Datono") through its wholly owned subsidiary Teyame AI Holdings Inc. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash component and equity component, split between common stock amounting to $12,000 and preferred stock amounting to $18,000 (to be issued), with an additional earnout component payable in the Company's preferred stock upon achievement of specified post-closing performance targets. As of March 31, 2026, 55,482 restricted shares of common stock and 424,856 pre-funded warrants convertible to common stocks were issued towards the $12,000 common stock issuance, whereas preferred stocks are yet to be issued. See note 5(B) for further details.

ii. Pre-Funded Warrants

&nbsp;&nbsp;&nbsp;&nbsp;● On February 26, 2026, the Company completed a
 registered direct offering pursuant to which it issued and sold an aggregate of 681,553
 securities at a purchase price of $5.81
 per security, consisting of 421,553
 shares of common stock and 260,000
 pre-funded warrants to purchase shares of common stock, which were exercised immediately upon issuance. The pre-funded warrants were issued
 in lieu of shares of common stock to certain investors whose purchase of common stock would otherwise have resulted in such investors
 exceeding applicable beneficial ownership limitations. Each pre-funded warrant had an exercise price of $0.00001
 per share, was immediately exercisable, and remained exercisable until exercised in full, subject to the beneficial ownership limitations
 set forth in the warrant agreement. See below (D) for details. The Company received net proceeds of approximately
 $3,563
 after deducting commissions and other offering expenses of approximately $397.
 Consistent with U.S. GAAP, the Company recorded the net amount within additional paid-in capital on the accompanying consolidated balance
 sheet as the securities met all the criteria for equity classification.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

The Company effected a 1-for-60 reverse split of its issued and outstanding common stock on February 10, 2026. The reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. The basic and diluted earnings consider the effect of reverse split across the reporting periods.

The movement of warrants during the quarters ended March 31 2026, and 2025, is shown below:

---

| | | | |
|:---|:---|:---|:---|
| <br>**Warrants** |<br>**Number of**<br>**Warrants** | **Weighted**<br>**Average**<br>**Exercise**<br>**price** | **Average**<br>**Remaining**<br>**Contractual**<br>**Term** |
| Outstanding on January 1, 2026 | 24765 | $509.05 | 4.74 |
| &nbsp;&nbsp;&nbsp;Granted | 260000 | 5.81 | 1511 |
| &nbsp;&nbsp;&nbsp;Exercised | (260000) | 5.81 | (1511) |
| Outstanding on March 31, 2026 | 24765 | 509.05 | 4.49 |
| **Exercisable on March 31, 2026** | **24765** | $509.05 | **4.49** |

---

---

| | | | |
|:---|:---|:---|:---|
| <br>**Warrants** |<br><br>**Number of**<br>**Warrants** |<br>**Weighted**<br>**Average**<br>**Exercise**<br>**price** | **Weighted**<br>**Average**<br>**Remaining**<br>**Contractual**<br>**Term** |
| Outstanding on January 1, 2025 | 65 | $119371 | 3.05 |
| Outstanding on March 31, 2025 | 65 | 119371 | 2.80 |
| **Exercisable on March 31, 2025** | **28** | $119371 | **2.57** |

---

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**B. Preferred Stock Series C**

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. ("Teyame") and Datono Mediacion S.L. ("Datono") through its wholly owned subsidiary Teyame AI Holdings Inc. The aggregate purchase price for the Acquired Companies is up to $50,000, of which upto $23,000 (including $5,000 contingent earn-out consideration) is payable through issuance of Series C preferred stocks. These preferred stocks are subject to conversion to common stock in the ratio of 1:1 (one common stock for one preferred stock) at the discretion of the issuer (the Company), in accordance with the terms and conditions set forth in the Share Purchase Agreement. See note 5(B) for details.

**C. Conversion of Debt to Equity**

During the quarter ended March 31, 2026, the holders of the 2025 Debentures converted a portion of the Debentures into 27,086,245 shares of common stock (451,437 shares post reverse-split of one-for-sixty, effective February 10, 2026). See note 9(B) for details.

**D. Equity Financing**

During the three months ended March 31, 2026, the Company completed several equity financing activities designed to strengthen liquidity, support working capital needs, and fund general corporate and strategic initiatives.

i. On February 26, 2026, the Company entered into a securities purchase agreement in connection with a registered
 direct offering, pursuant to which the Company agreed to sell an aggregate of 681,553
 securities at a purchase price of $5.81
 per security, for aggregate gross proceeds of approximately $3,960,
 before placement agent fees of 7%
 and other offering expenses. The offering consisted of 421,553
 shares of the Company's common stock and 260,000
 pre-funded warrants to purchase shares of common stock.

The pre-funded warrants were deemed cashless, and were issued in lieu of common stock to certain investors and are exercisable immediately for an aggregate of 260,000 shares of common stock, subject to customary anti-dilution adjustments, and remain exercisable until exercised in full. The pre-funded warrants also provide for cashless exercise in certain circumstances, including if an effective registration statement or current prospectus is not available for the issuance of the underlying shares.

The Company received net proceeds of approximately $3,563 after deducting commissions and other offering expenses of approximately $397. Consistent with U.S. GAAP, the commissions and offering costs are recorded as a reduction of additional paid-in capital within stockholders' equity.

ii. During the quarter ended March 31, 2026, the Company issued shares of its common stock pursuant to its At-the-Market
 Sales Agreement dated November 18, 2025. The Company sold an aggregate of 515,326
 shares of its common stock at the prevailing market prices, generating gross proceeds of approximately $5,522.
 In accordance with the terms of the Sales Agreement, the Company paid commission totaling 3%
 of the gross proceeds from each sale, in addition to other customary offering expenses. Total commissions and offering-related costs of
 approximately $135
 were incurred in connection with these issuances. The Company received net proceeds of approximately $5,387
 after deducting commissions and other offering expenses. Consistent with U.S. GAAP, the net proceeds are recorded in the additional paid-in
 capital within stockholders' equity.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**13) Segment Information**

**Schedule of operating segment**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br> March 31,** | **Three months ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Software services | $1630 | $1652 | $(22) | (1)% |
| Managed services and support | 1280 | 1982 | (702) | (35)% |
| Customer engagement services<sup>(\*)</sup> | 6875 | - | 6875 | 100% |
| Corporate and others | 70 | 70 | - | 0% |
| **Revenue** | $**9855** | $**3704** | $**6151** | **166%** |

---

<sup>(\*)</sup> represents segment acquired as part of business combination. See note 5(B) for details.

**Operating Results by Operating Segment**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
|  | **Software Services** | **Managed Services** | **Customer Engagement Services<sup>(\*)</sup>** | **Corporate and Others** | **Total** |
| **Revenue** | **1630** | **1280** | **6875** | **70** | **9855** |
| **Less:** |  |  |  |  |  |
| **Cost of revenue** | (1384) | (1016) | (4850) | (212) | (7462) |
| **Segmental gross profit/(loss)** | **246** | **264** | **2025** | **(142)** | **2393** |
| **Sales and marketing** | (116) | (74) | (47) | (1542) | (1779) |
| **General and administrative** | (307) | (80) | (1462) | (1368) | (3217) |
| **Bad debts** | - | - | - | (125) | (125) |
| **Research and development** | - | - | (30) | (55) | (85) |
| **Segmental profit / (loss)** | **(177)** | **110** | **486** | **(3232)** | **(2813)** |
| **Interest expenses** | - | - | (70) | (15) | (85) |
| **Depreciation and amortization** | (168) | (133) | (502) | (7) | (810) |
| **Other income** | - | - | 6 | 2 | 8 |
| **Forex loss** | - | - | - | (63) | (63) |
| **Changes in Fair Value** | - | - | - | (2435) | (2435) |
| **Loss before income taxes** | **(345)** | **(23)** | **(80)** | **(5750)** | **(6198)** |
| **Income tax** | - | - | - | - | - |
| **Loss after income taxes** | **(345)** | **(23)** | **(80)** | **(5750)** | **(6198)** |

---

<sup>(\*)</sup> represents segment acquired as part of business combination. See note 5(B) for details.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| **Particulars** | **Software Services** | **Managed Services** | **Corporate and others** | **Total** |
| **Revenue** | $**1734** | $**1900** | $**70** | $**3704** |
| **Less:** |  |  |  |  |
| **Cost of revenue** | (1543) | (1823) | (9) | (3375) |
| **Segmental gross profit** | **191** | **77** | **61** | **329** |
| **Sales and marketing** | (118) | (129) | (126) | (373) |
| **General and administrative** | (102) | (112) | (984) | (1198) |
| **Research and development** |  |  | (144) | (144) |
| **Segmental loss** | **(29)** | **(164)** | **(1193)** | **(1386)** |
| **Interest expenses** |  |  | (413) | (413) |
| **Depreciation and amortization** | (6) | (6) | (0) | (12) |
| **Other income** |  |  | 111 | 111 |
| **Loss before income taxes** | **(35)** | **(170)** | **(1495)** | **(1700)** |
| **Income tax** |  |  |  |  |
| **Loss after income taxes** | $**(35)** | $**(170)** | $**(1495)** | $**(1700)** |

---

**Revenue from top 5 customers**

**Schedule of concentration**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three months ended <br> March 31, 2026** | **Three months ended <br> March 31, 2026** | **Three months ended <br> March 31, 2026** | **Three months ended<br> March 31, 2025** | **Three months ended<br> March 31, 2025** |
| <br>**Customer** | **Amount** |  | **% of <br> Revenue** | **Amount** | **% of <br> Revenue** |
| Customer 1 | $2138 | <sup>(\*)</sup> | 22% | $754 | 20% |
| Customer 2 | 682 | <sup>(\*)</sup> | 7% | 659 | 18% |
| Customer 3 | 653 | <sup>(\*)</sup> | 7% | 266 | 7% |
| Customer 4 | 652 | <sup>(\*)</sup> | 7% | 233 | 6% |
| Customer 5 | $637 |  | 6% | $188 | 5% |

---

<sup>(\*)</sup> represents customer acquired as part of business combination. See note 5(B) for details.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**14) Legal Matters**

The Company is not involved in any action, arbitration and/or other legal proceedings that it expects to have a material adverse effect on the business, financial condition, results of operations or liquidity of the Company. All legal costs are expensed as incurred.

**15) Stock Based Compensation**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br> 2026** | **December 31,<br> 2025** |
| Opening share options outstanding | 2710 | 46 |
| Vested / granted during the period / year | 1 | 2668 |
| Forfeited / expired | - | (4) |
| **Closing share options outstanding** | **2711** | **2710** |

---

**Schedule of stock option activity**

The employee options balance available under the plan (for issuance) was 3,997,290 and 3,138,276 as of March 31, 2026, and March 31, 2025, respectively.

The following table summarizes the activities for our unvested options for the quarter ended March 31, 2026.

---

| | | |
|:---|:---|:---|
|  | **Number of**<br>**Shares** | **Weighted <br> average <br> Grant Date <br> Fair Value**<br>**Per Share** |
| Unvested on January 1, 2026 | 3 | $24222 |
| Vested | (1) | 24218 |
| Unvested on March 31, 2026 | 2 | $24222 |

---

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

The following table summarizes the activities for our unvested options for the quarter ended March 31, 2025.

---

| | | |
|:---|:---|:---|
|  | **Number of**<br>**Shares** | **Weighted <br> average<br> Grant Date <br> Fair Value**<br>**Per Share** |
| Unvested on January 1, 2025 | 7 | $24533 |
| Vested | (2) | 25425 |
| Unvested on March 31, 2025 | 5 | $24186 |

---

**16) Loss per share**

---

| | | |
|:---|:---|:---|
|  | **Three months ended** | **Three months ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Net loss attributable to common stockholders | $(6340) | $(1700) |
| Net loss attributable to non-controlling interest | $(24) | $- |
| Weighted average shares outstanding used in basic per common share computations | 930672 | 659 |
| Basic / Diluted EPS – Stockholders<sup>(\*)</sup> | $(6.81) | $(0.17) |
| Basic / Diluted EPS – Non-controlling interest<sup>(\*)</sup> | $(0.03) | $- |

---

\* Due to net loss position, basic and diluted weighted average shares outstanding are the same.

**17) Subsequent Events**

&nbsp;&nbsp;&nbsp;&nbsp;i. The Company issued 181,295
 shares of common stock and sold certain securities generating $484
 gross cash proceeds, and incurred expenses pertaining to the fund-raising amounting to $15.
 The net cash proceeds from the issuance remained $469.
 Consistent with U.S. GAAP, the net proceeds will be recorded in additional paid-in capital within stockholders' equity.

&nbsp;&nbsp;&nbsp;&nbsp;ii. On April 20, 2026, the Company paid $3,200
 towards purchase consideration payable for Teyame and Datono acquisition. See note 5(B) for details.

**HEALTHCARE TRIANGLE, INC.**

**Notes To Condensed Consolidated Financial Statements**

**(Unaudited)**

(In thousands except share and per share data)

**18) New Accounting Pronouncements**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Implemented

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments in this update provide a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current classified accounts receivable and contract assets. We adopted this ASU on a prospective basis effective January 1, 2026. While this ASU was adopted, we did not elect practical expedient permitted under this ASU. Therefore, the adoption has no impact on our consolidated financial statements.<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Not Yet Due

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. ASU No. 2025-06. In September 2025, the FASB issued ASU No. 2025-06, "Intangibles - Goodwill and Other
 - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software," which is intended
 to modernize internal-use software guidance by removing all references to project stages and by clarifying the thresholds entities apply
 to begin capitalizing costs. ASU No. 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within
 those annual reporting periods. Early adoption is permitted. The guidance can be applied on a prospective basis, a modified basis for
 in-process projects, or a retrospective basis. We are currently evaluating the impact of the standard on our consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. ASU No. 2024-03. In November 2024, the FASB issued ASU No. 2024-03, "Income Statement - Reporting Comprehensive
 Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses," which is intended
 to improve disclosures about a public business entity's expenses by requiring disaggregated disclosure, in the notes to the financial
 statements, of prescribed categories of expenses within relevant income statement captions. ASU No. 2024-03 is effective for fiscal years
 beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
 The new standard may be applied either on a prospective or retrospective basis. We are currently evaluating the impact of the standard
 on our consolidated financial statement disclosures.

Recent accounting pronouncements adopted or pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

**Item 2. Management's discussion and analysis of financial condition and results of operations.** 

*The following discussion summarizes the significant factors affecting the operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the related notes thereto, and the consolidated financial statements and the related notes thereto all included elsewhere in this Quarterly Report on Form 10-Q. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity, and capital resources, and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward looking statements as a result of various factors, including those discussed below and elsewhere in this report, and in the sections entitled "Note Regarding Forward-Looking Statements" and "Risk Factors" contained in this Quarterly Report on Form 10-Q and in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC")*

**Overview** 

Healthcare Triangle, Inc. (the "Company") is a leading healthcare information technology company focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry.

The Company was formed on October 29, 2019, as a Nevada corporation and then converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences ("HCLS") industry. The business commenced on January 1, 2020, after SecureKloud Technologies Inc, transferred its Life Sciences business to us. As of March 31, 2026, we had a total of 41 full time employees and 32 sub-contractors, including 36 certified cloud engineers, 25 Epic Certified EHR experts, 9 MEDITECH Certified EHR experts and 3 Admin sub-contractors. Many of the senior management team and the members of our board of directors hold advanced degrees and some are leading experts in the field of technology, investment banking and public markets.

During the period ended March 31, 2026, the Company effected a 1-for-60 reverse split of its issued and outstanding common stock on February 10, 2026. The reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share.

Our approach leverages our proprietary technology platforms, extensive industry knowledge, and healthcare domain expertise to provide solutions and services that reinforce healthcare progress. Through our platform, solutions, and services, we support healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and Life Sciences, biotech companies, and medical device manufacturers in their efforts to improve data management, develop analytical insights into their operations, and deliver measurable clinical, financial, and operational improvements.

We offer a comprehensive suite of software, solutions, platforms, and services that enables some of the world's leading healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to real-world evidence, and accelerate their digital transformation. We combine our expertise in the healthcare technology domain, cloud technologies, DevOps and automation, data engineering, advanced analytics, security, compliance, and governance to deliver platforms and solutions that drive improved results in the complex workflows of Life Sciences, biotech, healthcare providers, and payers. Our differentiated solutions, enabled by our intellectual property and delivered as a service, provide advanced analytics, data science applications, and data aggregation in these highly regulated environments in a more compliant, secure, and cost-effective manner to our customers.

Our deep expertise in healthcare technology allows us to reinforce our clients' progress by accelerating their innovation. Our healthcare IT services include Electronic Health Records (EHR) and software implementation, optimization, extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. Our 24x7 managed services are used by hospitals and health systems, payers, Life Sciences, and biotech organizations in their effort to improve health outcomes and deliver deeper, more meaningful patient and consumer experiences. Through our services, our customers achieve a return on investment in their technology by delivering measurable improvements. Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.

**Our Business Model** 

The majority of our revenue is generated by our full-time employees who provide Software Services and Managed Services and Support to our clients in the Healthcare and Life Sciences industry. Our Software Services include strategic advisory, implementation and development services, and Managed Services and Support include post implementation support and cloud hosting.

**Key Factors of Success** 

We believe that our future growth, market adoption, success, and the long-term value creation associated Teyame following the acquisition by Healthcare Triangle, Inc (HCTI) will depend on several strategic, operational and technological factors. These factors represent significant opportunities that management must successfully address in order to realize the expected benefits of the acquisition and accelerate the combined company's growth trajectory.

**Investment in scaling the business** 

We need to continuously invest in sales, and marketing to promote our solutions to new and existing customers in various geographies, and other operational and administrative functions in systems, controls and governance to support our expected growth and our transition to a public company. We anticipate that our employee strength will increase over time because of such investments.

On June 16, 2025 (the "Closing date"), Healthcare Triangle, Inc. through its wholly owned subsidiary Quantum Nexus Inc. (the "Company") and Niyama Healthcare, Inc., a Delaware corporation, a provider of Mental Health and Hospital Information Systems technology, across India, South East Asia, and Europe (the "Seller") entered into an Asset and Stock Transfer Agreement (the "Agreement"). Pursuant to the Agreement, the Company agreed to purchase from the Seller the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) the Seller's 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - Hospital Information Systems SaaS Provider as Seller's Equity (the "Transferred Equity"), as a whole and as a going concern in exchange for the Purchase Price (as defined below).

The total fair value of consideration transferred on the Acquisition Date was approximately $6,095, consisting of the following:

● Cash paid at closing and within 120 days after closing: $1,494

● Fair value of equity consideration (1,388,041 pre-reverse-split restricted common shares issued): $4,601

● Fair value of contingent consideration (earn-out): $0

The deferred cash payment was discounted to present value using a market-based discount rate. The earn-out has been provisionally valued at nil based on initial probability-weighted revenue forecasts. This amount is subject to revision within the measurement period ending June 16, 2026, as management finalizes its assessment of the earn-out targets and market-based inputs.

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. ("Teyame") and Datono Mediacion S.L. ("Datono") through its wholly owned subsidiary Teyame AI Holdings Inc. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash component and equity component, with an additional earnout component payable in the Company's preferred stock upon achievement of specified post-closing performance targets.

The cash consideration includes: (i) $3,000 paid during 2025 pursuant to an advance agreement dated December 3, 2025, (ii) $6,000 paid during January, 2026 (iii) $3,200 paid on April 20, 2026, and (iv) $2,800 payable on the earlier of the conditions being met as outlined in the Share Purchase Agreement, or six months from the date of the Share Purchase Agreement (but in no event prior to April 29, 2026).

The final determination of the fair values, purchase consideration, related income tax impacts and residual goodwill will be completed as soon as practicable, and within the measurement period of up to one year from the acquisition date as permitted under GAAP. Any adjustments to provisional amounts that are identified during the measurement period will be recorded in the reporting period in which the adjustment is determined.

**Successful Integration of Teyame into the Healthcare Triangle**

A critical factor to the success of the acquisition will be Healthcare Triangle's ability to effectively integrate Teyame's operations, technology platforms, people, and the go-to-market strategy into HCTI's broader healthcare operations. The integration process includes aligning product development roadmap, simplifying operational processes, consolidating administrative functions, and creating a combined portfolio of customer impacting solutions.

Healthcare Triangle expects the acquisition to enhance its capabilities in artificial intelligence-driven healthcare technologies, automation, data analytics, and intelligent workflow management. Successful integration will depend on maintaining operational continuity, retaining key personnel and customers, and minimizing disruptions during the transition period.

In addition, the integration of Teyame's AI-driven capabilities with HCTI's cloud infrastructure, data platforms, and healthcare technology services is expected to create cross-functional synergies that may improve scalability, customer engagement, and long-term recurring revenue opportunities.

**Cross-selling and customer expansion opportunities**

The acquisition enables Healthcare Triangle to cross-sell Teyame's solutions into its existing customer base while simultaneously introducing HCTI's broader portfolio of cloud, cybersecurity, managed services and data engineering to Teyame's customers.

This combined customer relationships may increase enterprise engagements and enhance our data, analytics and automation offerings. Healthcare organizations increasingly prefer integrated technology partners capable of delivering end-to-end digital transformation solutions, and the acquisition may strengthen HCTI's ability to provide such comprehensive offerings.

Future growth will depend on the Company's ability to execute coordinated sales and marketing initiatives, demonstrate measurable value to customers, and maintain high customer retention and satisfaction levels.

**Adoption of Artificial Intelligence (AI) and enhancement of our Healthcare Technology capabilities**

The acquisition of Teyame is expected to accelerate the pace of innovation and strengthen HCTI's strategic positioning within the rapidly growing healthcare artificial intelligence market. Through the acquisition, HCTI intends to expand its scalable AI-driven capabilities and enhance its portfolio of solutions focused on clinical workflow optimization, patient engagement, operational efficiency, predictive analytics, and intelligent automation.

As healthcare organizations increasingly adopt AI-enabled technologies to improve clinical outcomes, care delivery, streamline operations, and enhance decision-making, HCTI believes the combined technology solutions will support the expansion of differentiated service offerings across hospitals, health systems, and life sciences organizations. The acquisition is also expected to enhance HCTI's ability to integrate advanced analytics, automation, and data-driven intelligence into its broader healthcare technology ecosystem.

The Company's future success will depend on its ability to continuously enhance product functionality, maintain technological relevance in a rapidly evolving healthcare environment, and deliver measurable clinical, operational, and financial outcomes for customers. HCTI believes these capabilities will be important drivers of customer adoption, long-term retention, recurring revenue growth, and overall market expansion.

**Adoption of our solutions by new and existing customers** 

We believe that our ability to increase our customer base will enable us to drive growth. Most of our customers initially deploy our solutions within a division or geography and may only initially deploy a limited set of our available solutions. Our future growth is dependent upon our existing customers' continued success and renewals of our solutions agreements, deployment of our solutions to additional divisions or geographies and the purchase of subscriptions to additional solutions. Our growth is also dependent on the adoption of our solutions by new customers. Our customers are large organizations who typically have long procurement cycles which may lead to declines in the pace of our new customer additions.

**Subscription services adoption** 

The key factor to our success in generating substantial recurring subscription revenues in future will be our ability to successfully market and persuade new customers to adopt our Software as a Service ("SaaS") offerings. We are in the early stages of marketing our SaaS offerings such as DataEz, CloudEz and Readabl.AI, and do not yet have enough information about our competition or customer acceptance to determine whether or not recurring subscription revenue from these offerings will have a material impact on our revenue growth.

**Mix of solutions and software services revenues** 

Another factor to our success is the ability to sell our solutions to the existing software services customers. During the initial period of deployment by a customer, we generally provide a greater number of services including advisory, implementation and training. At the same time, many of our customers have historically purchased our solutions after the deployment. Hence, the proportion of total revenues for a customer associated with software services is relatively high during the initial deployment period. While our software services help our customers achieve measurable improvements and make them stickier, they have lower gross margins than solution-based revenue. Over time, we expect the revenues to shift towards recurring and subscription-based revenues.

**Components of Results of Operations**

**Revenues**

During the quarter ended March 31, 2026 and 2025, the Company generated revenues of approximately $9.85 million compared to revenue of $3.70 million respectively which represents an increase of $6.15 million or 166% compared to the previous year comparative quarter.

We provide our services and manage our business under these operating segments:

● Software Services

● Managed Services and Support

● Customer Engagement Services

● Corporate and Others

**Software Services** 

The Company earns revenue primarily through the sale of software services that is generated from providing strategic advisory, implementation, and development services. The Company enters into Statement of Work (SOW) which provides for service obligations that need to be fulfilled as agreed with the customer. The majority of our software services arrangements are billed on a time and materials basis, and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain software services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred and customer acceptance. We recognize revenue when we have the right to invoice the customer using the allowable practical expedient under ASC 606-10-55-18 since the right to invoice the customer corresponds with the performance obligations completed.

**Managed Services and Support** 

Managed Services and Support include post implementation support and cloud hosting. Managed Services and Support are a distinct performance obligation. Revenue for Managed Services and Support is recognized ratably over the life of the contract.

**Customer Engagement Services**

The Customer Engagement Services segment includes services rendered to financial institutions in connection with the promotion and distribution of banking and credit products; services provided as an external collaborator to insurance intermediaries in the distribution of insurance products; outbound and inbound telemarketing; customer acquisition campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services that support customers' digital customer-acquisition and customer-care strategies.

Under these arrangements, the company typically acts as an intermediary or service provider, identifying and contacting potential customers or insureds, explaining product features, collecting and submitting applications or leads, and performing related administrative tasks and customer-care activities in accordance with the instructions, scripts and quality standards agreed with each customer. Consideration may be in the form of commissions based on

approved and issued banking or credit products or concluded or renewed insurance policies, or service fees based on time-and-effort, unit-based pricing, fixed price per completed output, or milestone-based pricing, as specified in the contract.

Commission revenue is recognized when the company's services under the relevant transaction have been performed and the specified approval, issuance, conclusion or renewal conditions have been met under the contract. Revenue from time-based or unit-based services is recognized as the underlying services are performed and the corresponding measurable outputs are delivered in accordance with the contract. Revenue under fixed-price or milestone-based arrangements is recognized over me as the related services are performed and contractual milestones are achieved.

**Corporate and Others**

This segment includes Platform Services revenue, alongside unallocated corporate head office costs. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.

The revenue from Platform services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract's total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.

Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers' systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.

**Cost of Revenue**

Cost of revenue consists primarily of employee-related costs associated with the rendering of our services, including salaries, benefits and stock-based compensation expense, the cost of subcontractors, travel costs, cloud hosting charges and allocated overhead the cost of providing professional services is significantly higher as a percentage of the related revenues than for our subscription services due to the direct labor costs and costs of subcontractors. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities.

While we may grow our headcount overtime to capitalize on our market opportunities, we believe our increased investment in automation, electronic health record integration capabilities, and economies of scale in our operating model, will position us to grow our platform solutions revenue at a greater rate than our cost of revenue.

**Gross Margin**

In the current period, the gross margin generated by the Company has increased to 24% in the quarter ended March 31, 2026, as compared to 9% in the quarter ended March 31, 2025, respectively. Going forward, we expect the gross margin to continue to increase, as new contracts are being negotiated at higher margins and as a result, we expect future profit margins to increase materially over the next few quarters.

**Operating Expenses**

**Research and Development**

Research and development expense (majorly our investment in innovation) consists primarily of employee-related expenses, including salaries, benefits, incentives, employment taxes, severance, and equity compensation costs for our software developers, engineers, analysts, project managers, and other employees engaged in the development and enhancement of our cloud-based platform applications. Research and development expenses also include certain third-party consulting fees. Our research and development expense excludes any depreciation and amortization.

We expect to continue our focus on developing new product offerings and enhancing our existing product offerings. As a result, we expect our future research and development expense to increase in absolute dollars, although it may vary from period to period as a percentage of revenue.

**Sales and Marketing**

Sales and marketing expense consists primarily of employee-related expenses, including salaries, benefits, commissions, travel, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our employees engaged in sales, sales support, business development, and marketing. Sales and marketing expense also includes operating expenses for marketing programs, research, trade shows, and brand messages, and public relations costs.

We expect our future sales and marketing expenses to continue to increase in absolute dollar terms as we strategically invest to expand our business, although it may vary from period to period as a percentage of total revenues.

**General and Administrative**

Our general and administrative expenses consist primarily of employee-related expenses including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and stock-based compensation expenses, for employees who are responsible for management information systems, administration, human resources, finance, legal, and executive management. The general and administrative expenses also include occupancy expenses (including rent, utilities, and facilities maintenance), professional fees, consulting fees, insurance, travel, contingent consideration, transaction costs, integration costs, and other expenses. Our general and administrative expenses exclude depreciation and amortization.

In the nearest future, we expect our general and administrative expenses to continue to increase to support business growth. Over the long term, we expect general and administrative expenses to decrease as a percentage of revenue.

**Depreciation and Amortization Expenses**

Our depreciation and amortization expense consists primarily of depreciation of fixed assets, amortization of customer relationship and capitalized software development costs, and amortization of intangible assets. We expect our depreciation and amortization expense to increase as we continue to invest and expand our business organically and through acquisitions.

**Other Income (Expense), Net**

Other income (expense), net consists of finance cost and gains or losses on foreign currency.

**Deferred Revenues**

Advanced billings to clients in excess of revenue earned are recorded as deferred revenue until the revenue recognition criteria are met.

**Results of Operations**

The following tables set forth selected unaudited condensed consolidated statements of operations and comprehensive loss data and such data as a percentage of total revenues for each of the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31** | **Three Months Ended March 31** | **Three Months Ended March 31** | **Three Months Ended March 31** |
|  | **2026** | **% Sales** | **2025** | **% Sales** |
| Revenue | $9855 | 100% | $3704 | 100% |
| *Less:* |  |  |  |  |
| Cost of revenue (exclusive of depreciation /amortization) | 7462 | 76% | 3375 | 91% |
| Sales and marketing | 1779 | 18% | 373 | 10% |
| General and administrative | 3217 | 33% | 1198 | 32% |
| Bad debts expense | 125 | 1% |  | 0% |
| Research and development | 85 | 1% | 144 | 4% |
| Depreciation and amortization | 810 | 8% | 12 | 0% |
| Other income | (8) | 0% | (111) | (3)% |
| Changes in fair value | 2435 | 25% |  | 0% |
| Interest expense | 85 | 1% | 413 | 11% |
| Forex loss | 63 | 1% |  | 0% |
| **Net loss** | $**(6198)** | **(63)%** | $**(1700)** | **(46)%** |

---

**Revenue from operations**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended <br> March 31,** | **Three Months Ended <br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Revenue | $9855 | $3704 | $(6151) | 166% |

---

Revenue increased by $6.15 million, or 166% to $9.86 million for the quarter ended March 31, 2026, as compared to $3.70 million for the quarter ended March 31, 2025. Revenue from Software Services, Managed Services and Support, Insurance Mediation, Direct Marketing and Corporate and Others revenue have increased in the current quarter.

Our top 5 customers accounted for 49% of the revenue in quarter ended March 31, 2026, and 56% during quarter ended March 31, 2025, respectively.

The following table has the breakdown of our revenues for the quarter ended March 31, 2026, and 2025 for each of our top 5 customers.

**<u>Top Five Customers Revenue for quarter ended March 31, 2026 and 2025.</u>**

**(In thousands, except percentages)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended <br> March 31, 2026** | **Three months ended <br> March 31, 2026** | **Three months ended<br> March 31, 2025** | **Three months ended<br> March 31, 2025** |
| <br>**Customer** | **Amount** | **% of Revenue** | **Amount** | **% of Revenue** |
| Customer 1 | $2138 \* | 22% | $754 | 20% |
| Customer 2 | 682 \* | 7% | 659 | 18% |
| Customer 3 | 653 \* | 7% | 266 | 7% |
| Customer 4 | 652 \* | 7% | 233 | 6% |
| Customer 5 | 637 | 6% | $188 | 5% |

---

(\*) acquired as part of business combination during the period ended March 31, 2026.

The following table provides details of Customer 1 revenue by operating segments:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** <br> **March 31,** | **Three Months Ended** <br> **March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Software services | $- | $721 | $(721) | (100)% |
| Customer engagement services | 2138 |  | 2138 | 100% |
| Managed services and support |  | 33 | (33) | (100)% |
| **Total Revenue** | $2138 | $754 | $1384 | 184% |

---

Total revenue from Customer 1 increased by $1.38 million, or 184% to $2.14 million for the quarter ended March 31, 2026, as compared to $0.75 million for the quarter ended March 31, 2025. Software Services revenue decreased by $0.72 million or 100% to nil for the quarter ended March 31, 2026, as compared to $0.72 million for the quarter ended March 31, 2025. Customer engagement services revenue increased by $2.14 million, or 100% to $2.14 million for the quarter ended March 31, 2026, as compared to nil for the quarter ended March 31, 2025. Managed Services and Support revenue decreased by $0.03 million, or 100% to nil for the quarter ended March 31, 2026, as compared to $0.03 million for the quarter ended March 31, 2025.

**Cost of Revenue (exclusive of depreciation/amortization)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Cost of revenue (exclusive of depreciation/amortization) | $7462 | $3375 | $4087 | 121% |

---

Cost of revenue, excluding depreciation and amortization, increased by $4.09 million, or 121%, to $7.46 million for the quarter ended March 31, 2026, as compared to $3.38 million for the quarter ended March 31, 2025.

**Research and Development**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Research and development | $85 | $144 | $(59) | (41)% |

---

Research and Development expenses decreased by $0.06 million, or 41% to $0.09 million for the quarter ended March 31, 2026, as compared to $0.14 million for the quarter ended March 31, 2025.

**Sales and Marketing**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Sales and marketing | $1779 | $373 | $1406 | 377% |

---

Sales and Marketing expenses increased by $1.41 million, or 377% to $1.78 million for the quarter ended March 31, 2026, as compared to $0.37 million for the quarter ended March 31, 2025.

Sales and Marketing expenses for the quarters ended March 31, 2026, and 2025, were 1,779 and 373, of which advertisement expenses were $1,548 and $58 respectively.

**General and Administrative**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| General and administrative | $3217 | $1198 | $2019 | 169% |

---

General and Administrative expenses increased by $2.02 million, or 169% to $3.22 million for the quarter ended March 31, 2026, as compared to $1.20 million for the quarter ended March 31, 2025.

**Depreciation and Amortization**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Depreciation and amortization | $810 | $12 | $798 | 6650% |

---

Depreciation and Amortization expenses increased by $0.80 million, or 6650% to $0.81 million for the quarter ended March 31, 2026, as compared to $0.01 million for the quarter ended March 31, 2025.

**Interest Expense**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Interest expense | $85 | $413 | $(328) | (79)% |

---

Interest expenses decreased by $0.33 million, or 79% to $0.09 million for the quarter ended March 31, 2026, as compared to $0.41 million for the quarter ended March 31, 2025.

**Other income**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended<br> March 31,** | **Three Months Ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Other income | $8 | $111 | $(103) | (93)% |

---

Other income decreased by $0.10 million, or 93% to $0.01 million for the quarter ended March 31, 2026, as compared to 0.11 million for the quarter ended March 31, 2025.

**Changes in fair value**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | | |
|  | **March 31,** | **March 31,** | | |
|  | **(In thousands)** | **(In thousands)** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Changes in fair value | $2435 | $- | $2435 | (100)% |

---

Changes in fair value increased by $2.44 million to $2.44 million for the quarter ended March 31, 2026, as compared to $0 for the quarter ended March 31, 2025.

**Forex loss**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | | |
|  | **March 31,** | **March 31,** | | |
|  | **(In thousands)** | **(In thousands)** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Forex loss | $(63) | $- | $(63) | (100)% |

---

Forex loss increased by $0.06 million to $0.06 million for the quarter ended March 31, 2026, as compared to $0 for the year quarter ended March 31, 2025.

**Revenue, Cost of Revenue and Operating Profit by Operating Segment**

We manage and report our business under two operating segments which are Software services and Managed services and support.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended<br> March 31,** | **Three months ended<br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Software services | $1630 | $1652 | $(22) | (1)% |
| Managed services and support | 1280 | 1982 | (702) | (35)% |
| Customer engagement services | 6875 |  | 6875 | 100% |
| Corporate and others | 70 | 70 | - | 0% |
| **Revenue** | $**9855** | $**3704** | $**6151** | **166%** |

---

Revenue from Software services decreased by $0.02 million, or 1% to $1.63 million for the quarter ended March 31, 2026, as compared to $1.65 million for the quarter ended March 31, 2025. Revenue from Managed services and support decreased by $0.70 million, or 35% to $1.28 million for the quarter ended March 31, 2026, as compared to $1.98 million for the quarter ended March 31, 2025. Revenue from Customer engagement services increased by $6.87 million, or 100% to $6.87 million for the quarter ended March 31, 2026, as compared to nil for the quarter ended March 31, 2025.

**Factors affecting revenues of Software Services, and Managed Services and Support** 

Our strategy is to achieve meaningful long-term revenue growth through sales of Managed Services and Support to existing and new clients within our target market. In order to increase our cross-selling opportunity between our operating segments and realize long time revenue growth, our focus has shifted more towards Managed Services and Support which is of recurring nature when compared to Software Services segment which is of non-recurring nature. This also helps in retaining existing customers by leveraging our Managed Services and Support and Platform Services as a growth agent. This renewed focus on driving demand for subscription and platform-based model will help us in expanding our customer base and enhance customer retention which is a challenge for our existing Software Services segment. Software Services contracts are driven by Time and Material and on-site employees delivering services at customers location.

**Cost of Revenue**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended <br> March 31,** | **Three Months Ended <br> March 31,** | **Changes** | **Changes** |
|  | **2026** | **2025** | **Amount** | **%** |
| Software services | $1384 | $1543 | $(159) | (10)% |
| Managed services and support | 1016 | 1823 | (807) | (44)% |
| Customer engagement services | 4850 |  | 4850 | 100% |
| Corporate and others | 212 | 9 | 203 | 2256% |
| **Cost of revenue** | $**7462** | $**3375** | $**4087** | **121%** |

---

Cost of revenue from Software services decreased by $0.16 million, or 10% to $1.38 million for the quarter ended March 31, 2026, as compared to $1.54 million for the quarter ended March 31, 2025. Cost of revenue from Managed Services and Support decreased by $0.81 million, or 44% to $1.02 million for the quarter ended March 31, 2026, as compared to $1.82 million for the quarter ended March 31, 2025. Cost of revenue from Customer engagement services increased by $4.80 million, or 100% to $4.85 million for the quarter ended March 31, 2026, as compared to nil for the quarter ended March 31, 2025. Cost of revenue from corporate and others increased by $0.20 million, or 2,256% to $0.21 million for the quarter ended March 31, 2026, as compared to $0.09 million for the quarter ended March 31, 2025.

**Segment operating results by reportable segments were as follows:**

**Operating results by Operating Segment**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
|  | **Software Services** | **Managed Services** | **Customer Engagement Services\*** | **Corporate and Others** | **Total** |
| **Revenue** | **1630** | **1280** | **6875** | **70** | **9855** |
| **Less:** |  |  |  |  |  |
| **Cost of revenue** | (1384) | (1016) | (4850) | (212) | (7462) |
| **Segmental gross profit/(loss)** | **246** | **264** | **2025** | **(142)** | **2393** |
| **Sales and marketing** | (116) | (74) | (47) | (1542) | (1779) |
| **General and administrative** | (307) | (80) | (1462) | (1368) | (3217) |
| **Bad debts** |  |  |  | (125) | (125) |
| **Research and development** |  |  | (30) | (55) | (85) |
| **Segmental profit / (loss)** | **(177)** | **110** | **486** | **(3232)** | **(2813)** |
| **Interest expenses** |  |  | (70) | (15) | (85) |
| **Depreciation and amortization** | (168) | (133) | (502) | (7) | (810) |
| **Other income** |  |  | 6 | 2 | 8 |
| **Forex loss** |  |  |  | (63) | (63) |
| **Changes in Fair Value** |  |  |  | (2435) | (2435) |
| **Loss before income taxes** | **(345)** | **(23)** | **(80)** | **(5750)** | **(6198)** |
| **Income tax** |  |  |  |  |  |
| **Loss after income taxes** | **(345)** | **(23)** | **(80)** | **(5750)** | **(6198)** |

---

**(\*) Acquired as part of business combination during the period ended March 31, 2026.** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| **Particulars** | **Software Services** | **Managed Services** | **Corporate and others** | **Total** |
| **Revenue** | $**1734** | $**1900** | $**70** | $**3704** |
| **Less:** |  |  |  |  |
| **Cost of revenue** | (1543) | (1823) | (9) | (3375) |
| **Segmental gross profit** | **191** | **77** | **61** | **329** |
| **Sales and marketing** | (118) | (129) | (126) | (373) |
| **General and administrative** | (102) | (112) | (984) | (1198) |
| **Research and development** |  |  | (144) | (144) |
| **Segmental loss** | **(29)** | **(164)** | **(1193)** | **(1386)** |
| **Interest expenses** |  |  | (413) | (413) |
| **Depreciation and amortization** | (6) | (6) | (0) | (12) |
| **Other income** |  |  | 111 | 111 |
| **Loss before income taxes** | **(35)** | **(170)** | **(1495)** | **(1700)** |
| **Income tax** |  |  |  |  |
| **Loss after income taxes** | $**(35)** | $**(170)** | $**(1495)** | $**(1700)** |

---

**Due from related parties:**

On January 1, 2025, the Company entered into a Master Service Agreement with SecureKloud Technologies Inc. ("SKI") and SecureKloud Technologies Limited ("SKL). The initial term of the agreement is twenty-four months, which is extendable based on mutual consent. As per the Master Services Agreement, SKI and SKL provide technical resources according to the statement of work from the Company. Pricing is determined using a cost-plus model, with a markup of 18% on cost, to ensure that the transactions comply with the arm's length principle in accordance with the applicable transfer pricing regulations.

The balance outstanding from SecureKloud Technologies Limited as of March 31, 2026, and December 31, 2025, is $3,826. The balance is unsecured, non-interest bearing and is expected to be settled in the ordinary course of business, as outlined below:

$3,200 was advanced in connection with the design, develop and deliver an Integrated Health Advisory & Care Platform & Tools including certain artificial intelligence-enabled software tools and related intellectual property, intended to support the Company's current and future product offerings at a cost not-to-exceed $3,200, and

$626 for provision of certain services to the Company. These advances are expected to be settled in the ordinary course of business.

&nbsp;&nbsp;&nbsp;&nbsp;**C.** **Related party transactions:** 

Following are the transactions with related parties during the periods presented:

---

| | | | |
|:---|:---|:---|:---|
| **Related Parties** | **Nature of transactions** | **Quarter <br> ended <br> March 31, <br> 2026** | **Quarter <br> ended <br> March 31, 2025** |
| SecureKloud Technologies Limited, India | Services received | $539 | $912 |
|  | Amounts advanced |  | 1298 |
| SecureKloud Technologies, Inc. | Services received |  | 221 |
|  | Amounts advanced |  | 785 |
|  | Services rendered |  | 138 |
|  | Amounts collected by related party on behalf of the Company |  | 305 |
|  | Rent expenses paid |  | 43 |
| Blockedge Technologies, Inc. | Services received | 60 |  |
|  | Amounts advanced |  | 54 |
| Key management personnel | Remuneration | 235 | 400 |
| Board of Directors | Compensation | $55 | $55 |

---

**Liquidity and Capital Resources**

**Liquidity**

The current ratio measures a company's ability to pay off its current liabilities (payable within one year) with its total current assets such as cash, accounts receivable, and inventories. The Company's current ratio, as at March 31, 2026 is 0.90 compared to 1.33 as at December 31, 2025.

The Company's current debt equity ratio, as at March 31, 2026 financial statement is 0.21, compared to 1.08 as at December 31, 2025.

The Company does not have inventory and hence the quick ratio is the same as the current ratio.

**Sources of Liquidity**

---

| | | |
|:---|:---|:---|
|  | **As of <br> March 31,<br> 2026** | **As of <br> March 31,<br> 2025** |
| Cash and cash equivalents | $4315 | $6826 |

---

As of March 31, 2026, our principal sources of liquidity consisted of cash and cash equivalents of $4.31 million. We have financed our operations primarily through financing activity and operating cash flows. We believe our existing cash and cash equivalents generated from operations and financing activities will be sufficient to meet our working capital over the next 12 months. Our future capital requirements will depend on many factors including our growth rate, subscription renewal activity, the expansion of sales and marketing activities and the ongoing investments in platform development.

**Cash Flows**

The following table presents a summary of our consolidated cash flows provided by / (used in) operating, investing, and financing activities for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **As of <br> March 31,<br> 2026** | **As of <br> March 31,<br> 2025** |
| Cash flows used in operating activities | $(6864) | $(5557) |
| Cash flows used in investing activities | (6022) |  |
| Cash flows provided by financing activities | 9478 | 12363 |
| Cumulative translation adjustment | 98 |  |
| **Net increase / (decrease) in cash and cash equivalents** | $**(3310)** | $**6806** |

---

**Operating Activities**

Net cash used in operating activities during the three months ended March 31, 2026, was $(6.86) million compared to $(5.56) million for the three months ended March 31, 2025.

**Investing Activities**

Net cash used in investing activities was $(6.02) million for the three months ended March 31, 2026, compared to nil for the three months ended March 31, 2025.

**Financing Activities** 

Cash inflow from financing activities was $9.48 million for the three months ended March 31, 2026, compared to a net inflow of $12.36 million for the three months ended March 31, 2025.

**Off-Balance Sheet Arrangements** 

We do not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes as defined by Item 303(a)(4) of SEC Regulation S-K, as of March 31, 2026.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.** 

We did not have investments and do not utilize derivative financial instruments to manage our interest rate risks.

**Item 4. Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting**

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Chief Operating Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We, under the supervision of and with the participation of our management, including our Chief Operating Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Operating Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective as of March 31, 2026.

**Changes in Internal Control over Financial Reporting**

There were no changes to our internal control over financial reporting during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II**

**OTHER INFORMATION**

**Item 1. Legal Proceedings.** 

From time to time, we may be involved in routine litigation that arises in the ordinary course of business. We are not currently involved in any claim outside the ordinary course of business that is material to our financial condition or results of operations.

**Item 1A. Risk Factors.** 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K, filed with the SEC on April 16, 2026. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.** 

None.

**Item 3. Defaults Upon Senior Securities.** 

Not applicable

**Item 4. Mine Safety Disclosures.** 

Not applicable

**Item 5. Other Information** 

During the three months ended March 31, 2026, no director or officer adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408(a) of Regulation S-K.

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form S-](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_1.htm) [1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_1.htm) |
| 3.2 | [Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form S-1 (No. 333-259180),](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_2.htm) [filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_2.htm) |
| 3.3 | [Amendment to Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 to the Company's Registration](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_3.htm) [Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_3.htm) |
| 3.4 | [Certificate of Amendment to Certificate of Incorporation of Healthcare Triangle, Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K, filed with the SEC on August 1, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025070705/ea025137901ex3-1_healthcare.htm) |
| 3.5 | [Certificate of Correction to Certificate of Amendment to Certificate of Incorporation of Healthcare Triangle, Inc. (incorporated by reference to Exhibit 3.2 to the Company's current report on Form 8-K, filed with the SEC on August 1, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025070705/ea025137901ex3-2_healthcare.htm) |
| 3.6 | [Certificate of Amendment to Certificate of Incorporation of Healthcare Triangle, Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K, filed with the SEC on February 13, 2026s)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026016390/ea027697001ex3-1_healthcare.htm) |
| 3.7 | [Series A Super Voting Preferred Stock Certificate of Designation(incorporated by reference to Exhibit 3.4 to the Company's Registration](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_4.htm) [Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex3_4.htm) |
| 3.8 | [Series A Super Voting Preferred Stock Amended and Restated Certificate of Designations (incorporated by reference to Exhibit 3.5 to the](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000326/ex3_5.htm) [Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000326/ex3_5.htm) |
| 4.1 | [Form of Underwriter's Warrant (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1 (No. 333-](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000388/ex1_1.htm) [259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000388/ex1_1.htm) |
| 4.2 | [Form of Senior Secured 15% Original Issue Discount Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the](http://www.sec.gov/Archives/edgar/data/1839285/000160706224000003/ex4_1.htm) [Company's current report on Form 8-K, filed with the SEC on January 2, 2024)](http://www.sec.gov/Archives/edgar/data/1839285/000160706224000003/ex4_1.htm) |
| 4.3 | [Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company's current report on Form 8-K, filed](http://www.sec.gov/Archives/edgar/data/1839285/000160706224000003/ex4_2.htm) [with the SEC on January 2, 2024)](http://www.sec.gov/Archives/edgar/data/1839285/000160706224000003/ex4_2.htm) |
| 4.4 | [Description of Securities](http://www.sec.gov/Archives/edgar/data/1839285/000121390026044078/ea028419101ex4-4.htm) |
| 4.5 | [Form of Series A Warrant (incorporated by reference to Exhibit 4.1 to the Company's current report on Form 8-K, filed with the SEC on February 28, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025018926/ea023255201ex4-1_health.htm) |
| 4.6 | [Form of Series B Warrant (incorporated by reference to Exhibit 4.2 to the Company's current report on Form 8-K, filed with the SEC on February 28, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025018926/ea023255201ex4-2_health.htm) |
| 4.7 | [Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.3 to the Company's current report on Form 8-K, filed with the SEC on February 28, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025018926/ea023255201ex4-3_health.htm) |
| 4.8 | [Form of New Warrant (incorporated by reference to Exhibit 4.1 to the Company's current report on Form 8-K, filed with the SEC on October 8, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025097464/ea026071801ex4-1_healthcare.htm) |
| 4.9 | [Form of Advisor Warrant (incorporated by reference to Exhibit 4.2 to the Company's current report on Form 8-K, filed with the SEC on October 8, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025097464/ea026071801ex4-2_healthcare.htm) |
| 4.10 | [Form of Senior Unsecured Convertible Note (incorporated by reference to Exhibit 4.1 to the Company's current report on Form 8-K, filed with the SEC on November 21, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025113672/ea026676701ex4-1_healthcare.htm) |
| 4.11 | [Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company's current report on Form 8-K, filed with the SEC on February 27, 2026)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026021740/ea027905901ex4-1.htm) |
| 10.1 | [Asset Transfer Agreement, dated January 1, 2020 between the Company and SecureKloud Technologies, Inc. (incorporated by reference to](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_1.htm) [Exhibit 10.1 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_1.htm) |
| 10.2 | [Equity Purchase Agreement, dated May 8, 2020 between the Company and SecureKloud Technologies, Inc. (incorporated by reference to](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_2.htm) [Exhibit 10.2 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_2.htm) |
| 10.3 | [The Company's 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company's Registration Statement on Form S-](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_6.htm) [1 (No. 333-259180), filed with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_6.htm) |
| 10.4 | [Form of Grant (incorporated by reference to Exhibit 10.7 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_7.htm) [with the SEC on October 8, 2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_7.htm) |
| 10.5 | [IT Master Services Agreement effective as of May 1, 2017 between F. Hoffmann-La Roche Ltd and the Company (incorporated by](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_14.htm) [reference to Exhibit 10.14 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8,](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_14.htm) [2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_14.htm) |
| 10.6 | [Form of Statement of Work under Master Services Agreement between F. Hoffmann-La Roche Ltd and the Company (incorporated by](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_15.htm) [reference to Exhibit 10.15 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8,](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_15.htm) [2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000301/ex10_15.htm) |
| 10.7 | [Form of Common Stock Purchase Warrant to be issued to the Placement Agent for the Note and Warrant Private Offering (incorporated by](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000360/ex10_16.htm) [reference to Exhibit 10.16 to the Company's Registration Statement on Form S-1 (No. 333-259180), filed with the SEC on October 8,](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000360/ex10_16.htm) [2021)](http://www.sec.gov/Archives/edgar/data/1839285/000160706221000360/ex10_16.htm) |

---

---

| | |
|:---|:---|
| 10.8 | [Board Agreement, dated as of July 13, 2023, by and between the Company and Dave Rosa. (incorporated…the Company's current report on Form 8-K, filed with the SEC on July 14, 2023)](http://www.sec.gov/Archives/edgar/data/1839285/000160706223000365/ex10_1.htm) |
| 10.9 | [Asset Transfer Agreement, by and between Healthcare Triangle, Inc. and SecureKloud Technologies, Inc., dated October 21, 2024 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on October 25, 2024)](http://www.sec.gov/Archives/edgar/data/1839285/000121390024090797/ea021870801ex10-1_healthcare.htm) |
| 10.10 | [Employment Agreement between Healthcare Triangle, Inc. and Ms. Sujatha Ramesh, dated March 18, 2025. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on March 24, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000101376225001582/ea023545501ex10-1_health.htm) |
| 10.11 | [Employment Agreement between Healthcare Triangle, Inc. and Mr. David Ayanoglou, dated April 10, 2025 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on April 11, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025030806/ea023794501ex10-1_healthcare.htm) |
| 10.12 | [Asset and Stock Transfer Agreement, dated June 16, 2025, by and among Healthcare Triangle, Inc., through its wholly owned subsidiary QuantumNexis Inc., and Niyama Healthcare, Inc. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on June 23, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025056774/ea024660301ex10-1_healthcare.htm) |
| 10.13 | [Amendment No. 1 to Asset Transfer Agreement, dated August 28, 2025, by and between Healthcare Triangle, Inc. and Niyama Healthcare, Inc. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on September 2, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025082708/ea025532301ex10-1_health.htm) |
| 10.14 | [Form of Warrant Inducement Letter (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on October 8, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025097464/ea026071801ex10-1_healthcare.htm) |
| 10.15 | [Sales Agreement dated November 18, 2025 by and between Healthcare Triangle, Inc. and Spartan Capital Securities, LLC (incorporated by reference to Exhibit 1.1 to the Company's current report on Form 8-K, filed with the SEC on November 19, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025112546/ea026594402ex1-1_healthcare.htm) |
| 10.16 | [Form of Securities Purchase Agreement, dated as of November 20, 2025, by and between Healthcare Triangle, Inc. and the Investor(s) (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on November 21, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025113672/ea026676701ex10-1_healthcare.htm) |
| 10.17 | [Form of Registration Rights Agreement, dated as of November 20, 2025, by and between the Company and the Investor(s) (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K, filed with the SEC on November 21, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025113672/ea026676701ex10-2_healthcare.htm) |
| 10.18 | [Form of Securities Purchase Agreement, dated as of November 20, 2025, by and between the Company and the Investor(s) (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on November 21, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025113672/ea026676701ex10-1_healthcare.htm) |
| 10.19 | [Form of Registration Rights Agreement, dated as of November 20, 2025, by and between the Company and the Investor(s) (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K, filed with the SEC on November 21, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025113672/ea026676701ex10-2_healthcare.htm) |
| 10.20 | [Advance Agreement, dated December 5, 2025, among Healthcare Triangle, Inc., and Teyame AI LLC, a St Kitts and Nevis corporation (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on December 10, 2025)](http://www.sec.gov/Archives/edgar/data/1839285/000121390025119878/ea026910601ex10-1_healthcare.htm) |
| 10.21 | [Share Purchase Agreement, dated as of January 22, 2026 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on January 28, 2026)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026008594/ea027437301ex10-1_healthcare.htm) |
| 10.22 | [Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on February 27, 2026)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026021740/ea027905901ex10-1.htm) |
| 10.23 | [Form of Placement Agency Agreement (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K, filed with the SEC on February 27, 2026)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026021740/ea027905901ex10-2.htm) |
| 10.24 | [Platform Development Agreement, dated April 7, 2026, by and among Healthcare Triangle, Inc., SecureKloud Technologies Limited and Blockedge Technologies Inc. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed with the SEC on April 10, 2026)](http://www.sec.gov/Archives/edgar/data/1839285/000121390026042597/ea028595901ex10-1.htm) |
| 21.1\* | [List of Subsidiaries of the Company](ea029023801ex21-1.htm) |
| 31.1\* | [Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ea029023801ex31-1.htm) |
| 31.2\* | [Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea029023801ex31-2.htm) |
| 32.1\*\* | [Certification of the Principal Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea029023801ex32-1.htm) |
| 32.2\*\* | [Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ea029023801ex32-2.htm) |
| 101.INS\*\* | Inline XBRL Instance Document. |
| 101.SCH\*\* | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL\*\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF\*\* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\*\* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\*\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the iXBRL document). |

---

\* Filed herewith.

\*\* Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | HEALTHCARE TRIANGLE, INC. |
| Date: May 13, 2026 | */s/ Sujatha Ramesh* |
|  | Sujatha Ramesh |
|  | Board Director and Chief Operating Officer |
|  | (Principal executive officer) |
| Date: May 13, 2026 | */s/ David Ayanoglou* |
|  | David Ayanoglou |
|  | Chief Financial Officer |
|  | (Principal financial officer) |

---

## Exhibit 21.1

**Exhibit 21.1**

**LIST OF SUBSIDIAIRIES OF THE REGISTRANT**

1. Devcool Inc.

2. QuantumNexis Inc.

3. QuantumNexis Malaysia (SDN) BHD.

4. Ezovion Solutions (Private) Limited

5. Teyame AI Holdings Inc.

6. Teyame 360 S.L.

7. Datono Mediacion S.L.

8. Purpose Health Inc.

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER<br> THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION <br> 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Sujatha Ramesh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the
period ended March 31, 2026 of Healthcare Triangle, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board
of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ Sujatha Ramesh* |
|  | Name: | Sujatha Ramesh |
|  | Title: | Chief Operating Officer<br> (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER<br> THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION<br> 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, David Ayanoglou, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2026 of Healthcare Triangle, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation
of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board
of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ David Ayanoglou* |
|  | Name: | David Ayanoglou |
|  | Title: | Chief Financial Officer<br> (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<br> SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Healthcare Triangle, Inc. (the "Company") for the period ending March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ Sujatha Ramesh* |
|  | Name: | Sujatha Ramesh |
|  | Title: | Chief Operating Officer<br> (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO<br> 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<br> SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Healthcare Triangle, Inc. (the "Company") for the period ending March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | */s/ David Ayanoglou* |
|  | Name: | David Ayanoglou |
|  | Title: | Chief Financial Officer<br> (Principal Financial Officer) |

---